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ABSTRACT 
 
Objective – The present study aimed to determine if a treatment effect is present on 
speech outcomes in children with spastic cerebral palsy (CP) given 5 sessions of a 
manual therapy treatment protocol.  
Methods – A single-subject experimental design (ABAB) study was devised to establish 
the treatment efficacy of a manual therapy protocol on speech outcomes in children with 
spastic CP. The protocol was administered to 5 participants, 4-6 years old. It included 
five intercostal stretches administered in 15-minute sessions for five sessions.  During the 
withdrawal phase, a sham treatment was administered that included an equal dosage of 
treatment.  Measurements of sound pressure level (SPL) and Maximum Phonation 
Duration (MPD) of /a/ served as the primary outcomes. Secondary outcome measures 
included speech intelligibility, syllables per breath unit (SBU), and chest structure 
measurements.  
Results – Trend, level, variability, effect sizes, % of Non-Overlapping Data, and 
immediacy of effect were combined to support or refute each effect.  15 of 15 
demonstrations of effect for SPL, and 9 of 15 demonstrations of effect for MPD were 
located. This data demonstrate a positive effect on SPL and minimal support for an effect 
on MPD. Secondary outcome measures of SBU and chest mobility showed a positive 
treatment effect, while speech intelligibility and abdominal protrusion did not. 
Conclusions – This is the first known study to demonstrate a treatment effect in SPL and 
SBU using a manual therapy protocol, which provide evidence of a likely treatment effect 
in speech outcomes in children with spastic CP.   
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CHAPTER 1. 
INTRODUCTION 
 
The neuromuscular and musculoskeletal systems of children with cerebral palsy (CP) do 
not develop typically due to restrictions in their movement.  Specific to respiration to support 
speech, the development of the rib cage often occurs without intervention as children’s motor 
skills advance (Parham, 2013) to include oppositional motor movements and crossing midline. 
Often in children with CP, these changes do not occur without physical and occupational therapy 
intervention.   
In the treatment of respiratory function in children with CP, goals are considered 
achieved when the patient is able to maintain adequate oxygen levels without the support of a 
ventilator and/or range of motion (ROM) is adequate to prevent secondary impairments such as 
contractures (Pin, Dyke, & Chan, 2006; Theis, Korff, Kairon, & Mohagheghi, 2013). The 
respiratory support required for speech production exceeds that which is needed for life support. 
Thus, respiratory support treatment may be discontinued well before it is sufficient to support 
speech. As the physical therapist (PT) continues to address other issues, the speech-language 
pathologist (SLP) is left with a respiratory system that does not support speech production.  This 
study aims to determine if application of stretch to the chest wall structures will facilitate 
increased respiration to support speech production.   
Establishing EBP 
Although treatments in physical, occupational, and speech-language therapy have shown 
positive clinical change in children diagnosed with CP, many traditional methods are not 
supported by sufficient evidence to make firm treatment recommendations. Many research 
efforts offer little direction due to a paucity of consistency and specificity across the treatments 
studied. The heterogeneity of the studies available regarding speech in patients with spastic CP 
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makes it difficult to draw definitive conclusions regarding treatment efficacy. The weaknesses 
described further contribute to the lack of research progress in this population and treatment area. 
More clearly defined treatment protocols used in both direct and systematic replication could 
strengthen both the certainty of our knowledge and the generalization of treatments to the entire 
population of children with spastic dysarthria. Well defined populations, number of participants, 
standardized treatments, and outcome measures could contribute to the development of treatment 
plans supported by empirical research (Levy, 2014; Solomon & Charron, 1998). Morgan, Hodge 
and Pennington (2015) discuss how the deficiency of tools for eliciting connected speech in 
children with dysarthria limits the measurement of intelligibility and associated measures. 
Due to their widely accepted methodology in the establishment of evidence-based 
practices (EBPs) and contribution in the identification of cause-effect relationships, randomized 
control trials are highly valued by publishers and researchers (Byiers, Reichle, & Symons, 2012).  
However, implementing rigorous designs and translating statistical data obtained in these studies 
to populations of individuals with disabilities have proved difficult and sometimes misleading 
(Attanasio, 1994; Byiers et al., 2012).  Group studies require large, randomly selected, 
homogeneous, representative groups of participants (Hinkle, Wiersma, & Jurs, 2002).   Given the 
heterogeneous nature of the population of individuals with CP and other severe motor 
impairments (e.g. variable symptomology, function, and maturation), attaining an appropriately 
powered homogeneous sample is nearly impossible (Solomon & Charron, 1998). 
Another concern caused by the use of group designs is the strict experimental control 
between participants that may prevent them from receiving optimal treatments (Attanasio, 1994). 
In neurological rehabilitation, patterns of cognitive, behavioral, and sensorimotor impairments in 
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patients with the same diagnosis vary, resulting in diverse presentations of function; therefore, 
treatment should reflect these differences (Perdices & Tate, 2009).   
Omitting or failing to adhere to these crucial experimental design components could 
greatly compromise generalization and internal and external validity (Attanasio, 1994).  
Furthermore, if rigorous control were achieved, it likely would not reflect the variability present 
in clinical practice settings.  In addition to participant selection and rigid treatment protocols, the 
feasibility of large-scale studies may be limited due to financial, time, and personnel resources 
(Kazdin, 2010).   
Some have argued the interpretation of the inferential statistics in large group studies has 
prevented the establishment of a research base applicable to clinical issues (Attanasio, 1994) and 
masks individual variability (Perdices & Tate, 2009).  The statistics obtained in such studies give 
the probability of obtaining the same results given the same population if the exact study were to 
be replicated (Attanasio, 1994; Hinkle et al., 2002).  The use of manipulated data in measures of 
central tendency and statistical significance tells little about the effect a treatment has on an 
individual, thus making direct application to a member of a heterogeneous group with 
heterogeneous symptoms unclear.  The context of the treatment and individual variability is lost 
as inferential statistics tell only whether a difference in group averages is present (Hinkle et al., 
2002). 
Because ideal treatment methods are difficult to implement in large-group studies and 
statistics are challenging to interpret, clinicians have often defaulted to accepted traditional 
treatments that have little to no research support. In fact, rather than attempting new treatments 
that have limited research support, SLP’s sometimes choose to continue to use traditional 
treatments that research has proven ineffective, likely due to confirmation bias (Kazdin, 2010). 
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This practice limits the interventions provided to patients and prevents them from receiving the 
most appropriate care.  The scientific method as demonstrated in publication offers a mechanism 
for self-correction that is not available to the practicing therapist in the clinic (Kahmi, 2011). As 
the push continues toward EBP and implementation science, practitioners must reevaluate their 
methods and may consider the research available using single subject experimental designs. 
Populations with increased heterogeneity or rarity would not be viable in large group 
designs (Byiers et al., 2012). Therefore, direct analysis of an individual’s data may prove useful 
in the identification of treatment effectiveness (Byiers et al., 2012; Heyvaert & Onghena, 2013), 
determination of usefulness in clinical settings (Kazdin, 2010), description of individual changes 
(Kazdin, 2010), and the inclusion of environmental variables (Byiers et al., 2012).  Other 
strengths of single-subject designs include: exposure of the independent variable to an 
individual’s variability, direct interpretation of the data, and contribution to the establishment of 
empirically validated treatments (Perdices & Tate, 2009). 
Inclusion of vital design components enables strong, high-quality research results 
applicable to the specified individuals.  Designs including multiple phases across participants 
allow simultaneous replication and opportunity for multiple demonstrations of effect, thus 
reducing threats to internal and external validity (Byiers et al., 2012; Heyvaert & Onghena, 2013; 
Perdices & Tate, 2009).  Temporal staggering of the phases and randomization of the moments 
of phase change further control for internal validity confounds (Heyvaert & Onghena, 2013) by 
improving causal inference.  Blinding of participants and examiners to the study’s purpose 
provides additional safeguard against internal and external threats (Tate et al., 2013).  Lastly, 
replication across participants reduces external validity threats and improves generalization 
(Byiers et al., 2012). 
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Statement of the problem 
Examination of the literature specific to physical therapy, respiration, and CP 
predominantly yielded results regarding positioning (e.g. Littleton, Heriza, Mullens, Moerchen, 
& Bjornson, 2011) and airway clearance (e.g. Bilan & Poorshiri, 2013). While, there is a large 
amount of clinical and anecdotal information available regarding a stretch protocol to improve 
speech and swallowing in children with severe motor impairments, there is no literature that 
systematically investigates whether any manual therapy does in fact, contribute to improved 
speech output. Only one article has directly evaluated the role of physical therapy in addressing 
chest expansion and the effects of stretch on the intercostal muscles (Jerome, Passi, & Koli, 
2013).  The current study represents Phase 2 research to design a treatment that would enable 
participants with severe motor impairments, such as CP, to produce speech and language that 
will not only make them more effective communicators, but also improve their quality of life. 
 The present study aimed to determine if a manual therapy treatment protocol provided by 
a trained SLP would increase speech outcome measures of intensity (SPL) and duration (s) in the 
maximum phonation of children diagnosed with spastic CP.  Secondary outcome measures 
included speech intelligibility and syllables per breath unit (SBU) to assess functional changes, 
and chest expansion and abdominal protrusion to assess ROM and structural changes. 
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CHAPTER 2. 
LITERATURE REVIEW 
 
Due to the limited research available, the following review evaluates the need for SLPs to 
address structural constraints contributing to poor respiratory support for speech in children with 
CP and the possibility of manual therapy being the tool they use to do so.  More specifically, the 
American Speech-Language and Hearing Association’s (ASHA) position regarding SLPs 
treating speech-breathing disorders, typical and atypical chest wall development, the role of the 
rib cage in respiratory function, and physical and speech therapy treatments addressing 
respiratory function in patients with neuromuscular disorders will be discussed. 
Respiratory Treatment Guidelines for SLPs 
 ASHA published “Medical Review Guidelines” to guide health plans in claim review and 
policy development thus influencing clinical practice activities. The guidelines indicate 
intervention for children with CP may include “receptive and expressive language skills, 
articulation, and development of the proper breath support for speech and swallowing, as well as 
introducing augmentative and alternative communication (AAC) systems, such as symbol charts 
or speech synthesizers” (p.35) (American Speech-Language-Hearing Association, 2011). 
Portions of the guidelines reinforce the “Code of Ethics” principles to provide patients high 
quality care (American Speech-Langauge-Hearing Association, 2010). 
In addition to the Medical Review Guidelines, ASHA details a SLP’s “Scope of 
Practice.” Broad examples of using data to guide decision-making, formulating treatment plans, 
and collaboration with other professionals, are outlined (American Speech-Langauge-Hearing 
Association, 2007; American Speech-Language-Hearing Association, 2011). However, no 
specific information regarding the treatment of children with motor deficits or respiratory 
concerns is included.  Because ASHA chooses to focus on high quality treatment, data driven 
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decisions, and EBP it is important for those in the research community to fill the gaps in current 
research to address children with motor and respiratory deficits affecting speech production. 
Cerebral Palsy 
CP is the leading cause of severe physical disability in children, affecting about 500,000 
in the United States (Koman, Smith, & Schilt, 2004). Often, the cause is unknown; however, 
known causes include: birth complications, pre-maturity, trauma, intra-cranial hemorrhage, and 
infection. Many children with CP exhibit one or a combination of the following impairments: 
reduced cognition, decreased motor function, poor vision and hearing acuity, hypersensitivity to 
touch or pain, and gastrointestinal complications (Krigger, 2006).  Spastic CP, which comprises 
approximately 70-80% of those cases, results from a lesion to periventricular white matter of the 
brain prior to age 2 and causes motoric impairment characterized by involuntary muscle activity, 
poor coordination, muscle weakness, and rigidity. Spasticity is a hyper-excited tonic stretch 
reflex that prevents the stretching of muscles and tendons which may negatively impact a 
patient’s function, pain level, and quality of life (Krigger, 2006). 
Secondary musculoskeletal complications, such as contractures and joint displacement, 
develop due to movement restrictions and postural abnormalities caused from spasticity, 
immobility, and adaptive soft tissue changes (Abdel-Hamid & Zeldin, 2013; Koman, Smith, & 
Schilt, 2004; Krigger, 2006).  These impairments complicate the coordination and muscle 
weakness concerns in patients with CP (Massery, 1991). The resulting shortened muscle length 
and involuntary muscle contraction manifests as muscle stiffness resulting in decreased joint 
mobility and increased resistance to passive joint movement (Katalinic, Harvey, & Herbert, 
2011; Theis et al., 2013). Interventions addressing the primary abnormalities and prevention of 
secondary complications may include neuromuscular electrical stimulation, serial casting, 
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orthotics, bracing, speech therapy, occupational therapy, physical therapy, drug therapies, 
orthopedic surgery, and neurosurgery (Koman et. al., 2004).  The goal of these therapies are not 
to achieve typical function, but to increase the function with early, intensive management 
(Krigger, 2006).  
Speech in children diagnosed with CP, often described as dysarthric, is characterized by 
poor intelligibility and shortened utterances due to interactions of cognition, language, and 
speech development (Hustad, Schueler, Schultz, and DuHadway, 2012).  Dysarthria affects the 
motor control of the speech subsystems (Pennington, James, McNally, Pay, & McConchaie, 
2009). Speech motor control deficits in children with CP have not been thoroughly studied (Lee, 
Hustad, & Weismer, 2014), leaving clinicians without sufficient evidence to make treatment 
decisions.  In regards to respiratory function, children with CP have shallow, irregular breathing 
patterns and often speak on residual air. Their voices are lower in pitch, often are harsh or 
breathy, and are sometimes hypernasal (Pennington et al., 2009). Also, there a subset of children 
with CP have the cognition and language abilities to enable longer, more complex utterances; 
however, they do not have the anatomical and physiological support to enable the needed 
respiratory volume for those utterances (Maner, Smith, & Grayson, 2000; Smith, 2006).  
Speech Breathing and CP 
Hixon and Hoit (2000) stressed the importance of SLPs’ examination of the speech 
breathing mechanism in order to better understand the patient’s respiratory system, evaluate 
current physical status, determine prognoses, and develop treatment plans in patients with speech 
breathing disorders. The anatomical relationships of respiratory structures that develop as a result 
of decreased range of motion (ROM) and compensatory postures further suggest treatment in this 
population should focus on function and ROM.  Additionally, Parham (2013) described 
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respiratory development as foundational to the production of speech-related sounds and 
reiterated that relying on the adult literature when making treatment decisions for a developing 
system is not valid.  
A recent study by Lee et al. (2014) using a multiple speech subsystems approach 
concluded the articulatory system contributed the most to speech intelligibility. However, only 
articulatory, resonatory, and phonatory systems were included in the analyses. The study did not 
include the contributions of the respiratory system (J. Lee et al., 2014). In describing speech as a 
result of the integration of multiple body systems, Massery (2012) indicated respiratory function 
is the foundation for intelligible speech in populations with neuromuscular impairments.  This 
fact should direct the focus of treatment because there is a high incidence of respiratory 
dysfunction in children diagnosed with CP, evidenced by it being the leading cause of death in 
this population (Jerome et al., 2013).  
There is minimal literature addressing treatment of speech breathing in children with CP. 
As a matter of fact, there is a body of literature that describes the lack of research and the 
difficulties in completing research with these children in general (e.g. Butler and Darrah, 2001; 
Knox, 2002). Knox and colleagues (2002) reported the variation of motor disorders and ill-
defined treatment methods as problematic in determining efficacy of PT in children with CP. 
Butler and Darrah (2001) cited lack of discrete treatment dosages, nonspecific and variable 
treatment procedures, inconsistent treatment conditions, large range of therapists’ skill levels, 
and the complications of the patient’s growth and maturation.  
Normal Chest Wall Development 
Speech is a multi-system event requiring complex coordination of the respiratory, 
phonatory, resonatory, and articulatory systems to produce intelligible utterances to effectively 
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and efficiently communicate. Although respiration is deemed the foundation of speech 
production, it is important to consider that breathing is the primary function of the respiratory 
system. Therefore if breathing is compromised, reduction or inability to participate in other 
activities occurs (Hodges & Gandevia, 2000).  
The respiratory system’s function in speech production is to provide sufficient pressure 
beneath the level of the vocal folds to enable their vibration thus producing sound for vowel 
production and air pressure for consonant production  (Solomon & Charron, 1998). The chest 
wall composed of the rib cage, diaphragm, and pectoral muscles, moves as a unit to achieve 
optimum expiratory capacity (Hixon, 1973). 
Rib cage structure.  The ribs are elastic arches of bone that comprise the majority of the 
thoracic skeleton. The “true” ribs are the first seven that connect the sternum in the front of the 
body to the vertebrae posteriorly.  Below, the rib cage transitions to the false and floating ribs. 
The intercostal muscles fill the space, connecting adjacent ribs. The amount of intercostal space 
correlates to the age and mobility of the child.  Superficial rib cage muscles contribute to 
inspiratory force and stiffen to optimize diaphragm function.  The internal rib cage muscles 
along with the abdominals work together to maximize expiratory force for phonation (Hixon & 
Hoit, 2000). The vocal folds and support structures maintain appropriate airway opening by 
adducting and abducting to optimize voicing, balance vocal tension and airway pressure, and 
stabilize thoracic pressure (Massery, 2011). 
The shape, angle, and motion of the infant rib cage vary significantly from that of an 
adult (See Figure 1). In typical development, normal movement patterns and gravity contribute 
to muscular and skeletal development of the rib cage. Shape and volume changes in the thoracic 
cavity occur when the ribs elevate and rotate causing displacement of the sternum.  The 
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progression of development relies on joint mobility, movement of body parts (ex. swinging arms 
opposite the legs when walking or crawling), and rotation of upper and lower body structures 
across midline.  This progression includes increasing the rib-space, lengthening of the rib cage, 
and changing shape from triangular to rectangular as the infant matures (Massery, 1991).   
Additionally, other bones and muscles comprise the chest wall unit. The sternum, 
thoracic vertebrae and pectoral girdle complete the skeletal components. Furthermore, scalenes, 
subclavius, pectoralis major, pectoralis minor, serratus anterior, levatores costarum, serratus 
posterior superior, and latissimus dorsi complete the inspiratory musculature. And the transverse 
thoracis, subcostals, serratus posterior inferior, quadratus lumborum, and latissimus dorsi 
complete the expiratory musculature (Hixon & Hoit, 2000). 
 
Figure 1. Illustration by Rob Fedirko. Reproduced with permission from: Litman, R. and Giles, 
M. Developmental Physiology and Pharmacology, in Basics of Pediatric Anesthesia, Ronald S. 
Litman (editor), Philadelphia, 2015.  Reprinted with permission.  
 
Rib cage function. Because a large portion of the ribs is adjacent to the lungs, Hixon 
(1973) concluded rib cage motion is the primary force contributing to expiratory volume. Others 
demonstrated this relationship by assessing the correlation between the ratios of upper to lower 
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chest wall measures to forced vital capacity measures. Results revealed a significant relationship 
between chest wall structure and respiratory efficiency (Park, Park, Rha, Park, & Park, 2006).  
The superficial muscles produce inspiratory force, while deep muscles produce 
expiratory force. Movement of the rib cage wall relies on the mobility of the rib joints, vertebral 
joints, and the anterior rib articulations. The abdominals and passive recoil also contribute to 
both inspiratory and expiratory movements. Hixon and Hoit (2000) further stress the importance 
of upright body positioning in maximizing rib cage wall function. 
Abdominal muscles. It is important to note the abdominal muscles additionally play an 
important role in respiratory function.  The typical orientation of the abdominal muscles 
capitalize on gravity and mechanical advantage to achieve coordinated inspiratory and expiratory 
movements (Massery, 1991). Actions of the rib cage transport air more efficiently than 
abdominal motions due to its orientation to the lungs (Solomon & Charron, 1998).  
Rib cage versus abdominal contributions. Studies evaluating rib cage versus 
abdominal contributions have systematically supported Solomon and Charron’s (1998) 
conclusion that chest wall ROM is more valuable for speech production. Six healthy adult males 
with no anatomical or physiological speech deficits were studied. Displacements of the ribs, 
lungs, and abdomen were compared in singing, reading, and conversation conditions. Chest wall 
kinematic measures indicated rib cage motion is the primary force contributing to expiratory 
volume (Hixon, 1973). Others attempted to differentiate child versus adult kinematics in speech 
breathing and found similar results. Stathopoulos and Sapienza (1997) asked participants to 
produce the syllable /pa/. Aerodynamic and acoustic measurements were used in conjunction 
with kinematic measures to provide specifics regarding normal speech production in children 
versus adults. The data indicated approximately 82% contribution in children four to eight years 
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old. Hoit, Hixon, Watson, and Morgan (1990) had similar findings in participants four to 
fourteen years old. They assessed speech breathing in normal children in spontaneous speaking 
and reading conditions. Their results solidified the support that speech breathing in healthy 
children was produced with greater excursions than that of adults. Each of these studies provides 
evidence to support the focus of speech therapy on the anatomy and physiology of the rib cage to 
address respiratory dysfunction. 
Diaphragm. Massery (2006) discussed the diaphragm is a sheet of muscle that separates 
the thoracic and abdominal cavities. It functions concurrently to maintain trunk control, 
maximize inhalation and support gastrointestinal functions. The diaphragm depends on the 
intercostals and abdominals to generate pressure changes between the cavities during quiet 
inhalation.  It provides two-thirds to three-fourths of the tidal volume during quiet breathing; 
however, it serves a less prominent role in the controlled breathing required for speech 
production (Massery, 2006). Others have reported that the chest structure and abdominal 
structure approach more typical proportions, the diaphragm can support breathing for speech 
more efficiently (Druz & Sharp, 1981; Massery, 2006; Solomon & Charron, 1998). Postural, 
tonal, and mobility differences influence atypical development of the chest wall structure 
resulting in less efficient function. 
Atypical Chest Wall Development 
The neuromuscular and musculoskeletal systems of children with CP do not develop 
typically due to muscle imbalance, increased tone, decreased ROM, increased reflexes weakness, 
and fatigue that prevent or delay the typical developmental sequence (Koman et al., 2004; 
Solomon & Charron, 1998).  Weak abdominal muscles and poor positioning further contribute to 
rib cage flaring, which inhibits respiratory mechanics including chest expansion, lung volume, 
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and the efficacy of the diaphragm (Massery, 1991; Solomon & Charron, 1998). Retraction of the 
intercostal spaces, ribs, and sternum prevent optimum lung pressures (Massery, 1991; Park et al., 
2006). These musculoskeletal deviations result in a bell-shaped chest wall causing restrictive, 
rather than obstructive, respiratory dysfunction and a paradoxical breathing pattern (Park et al., 
2006). Time spent in a flexed position increases compensatory posturing contributing to the use 
of additional abnormal tone (Workinger & Kent 1991). Also, an unstable rib cage forces other 
muscles to compensate thus preventing variety and more refined movements (Donato et al. 
2008). Workinger and Kent (1991) detailed worsening vocal quality and loudness as children 
with CP develop due to increased use of compensatory recruitment of abnormal postures and 
musculature.  Each of these deviations contributes to shallow inhalation and poorly coordinated 
exhalations resulting from immobility of the chest wall (Massery, 2006).  
Hixon (1973) noted speech-breathing deviation could be the primary basis for speech 
deficits in many individuals with severe motor deficits. Small vital capacities have been reported 
in children diagnosed with spastic or athetoid CP (Hardy, 1961), suggesting shorter phonation 
durations (Workinger & Kent, 1991), which may impact speech intelligibility.  Contributing to 
these breathing differences, a stiff chest wall affects the efficiency of respiration in patients 
diagnosed with CP (Hardy, 1961). Furthermore, Druz and Sharp (1981) described gravity as the 
stimulus for the stretching of human respiratory muscles and increased muscle activity, which 
would explain the influence of body position on ventilation and volume exchange.  
Few have reported the clinical implications of deviations in chest wall structure on 
respiratory mechanics and efficiency.  Park and colleagues (2006) compared the ratios of upper 
to lower chest walls in 112 children with spastic CP and 112 normally developing children, ages 
ranging from 32-43 months.  Results indicated children with CP possess a significantly smaller 
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upper to lower chest ratios when compared to their typical peers point to underdevelopment of 
the upper chest wall.  The group concluded that chronic hypoventilation, reliance on the 
abdominals for breath support, and paradoxical breathing patterns likely contributed to the 
development of inadequate chest configurations (Park et al., 2006).  
Neuromotor control. The upper motor neuron damage present in children with CP 
results in decreased input to reticulospinal and corticospinal tracts. The neurological mechanisms 
and mechanical properties of muscle are altered due to upper motor neuron damage resulting in 
loss of function due to a decrease in the number of effective motor units, and tonal abnormalities 
(J. H. Carr, Shepard, & Ada, 1995; Miller, 2007). Another consequence is a loss of inhibitory 
input resulting in spasticity.  Spasticity is an increase in muscle activity resulting in a resistance 
to stretch which presents as increased tone (Koman et al., 2004). It results in structural deviations 
in the muscle itself including a 50% reduction in muscle fiber length, fewer muscle fibers, loss of 
sarcomeres, and a longer tendon (see Figure 2) (J. H. Carr et al., 1995; Miller, 2007). Often 
spasticity develops slowly after the neurological insult and is not an immediate result of the 
lesion. This suggest that spasticity is an adaptation rather than a consequence of the insult, and 
targeting prevention of these adaptations could increase motor function insult (J. H. Carr et al., 
1995). 
Carr et al. (1995) attributes the clinical presentation of spasticity to both disordered motor 
control and soft tissue changes.  They suggest that immobility is the major consequence of the 
brain lesion and that maintenance of soft tissue length should be maintained through active 
stretch and supplemented with passive stretch when active means are not possible due to the 
impairment.  
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 Neuroplasticity or the brain’s ability to reorganize after insult is an intrinsic property of 
the central nervous system (L. J. Carr, Harrison, Evans, & Stephens, 1993); however, many 
factors contribute to neurological reorganization in children including: age of insult, 
environment, intervention, type of lesion, location of lesion, and the  
 
Figure 2. A-Typical muscle structure; B-Muscle structure of an individual with prolonged 
spasticity. From Cerebral Palsy (p.106), by Miller, F., 2007, New York, NY: Springer Science 
and Business Media, Inc. Copywright 2005 vy Springer Science+Business Media, Inc. Reprinted 
with permission. 
 
presence of healthy tissue (Anderson, Spencer-Smith, & Wood, 2011).  Researchers are currently 
using functional magnetic resonance imaging (fMRI) to determine whether structural changes 
occur given interventions such as constraint-induced movement therapy (e.g. Sterling et al., 
2013), intensive strength training (e.g. Lee et al., 2014), and virtual reality therapy (e.g. You et 
al., 2005) in children with CP. 
Results in the current literature are promising; however, small sample sizes, 
heterogeneous groups, insensitive behavioral outcome measures, and short follow-up periods 
preclude definitive answers. Carr et al. (1993) showed evidence of central motor pathway 
reorganization using electromyography (EMG) responses in 21 of 33 children diagnosed with 
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hemiplegic CP. They described further that the corticospinal projection from the intact 
hemisphere branched to innervate the motor neuron of the damaged hemisphere. You et al. 
(2005) measured cortical activation using fMRI and demonstrated evidence of neuroplastic 
changes by eliminating atypical cortical activations in children with hemiparetic CP. Another 
research team used fMRI on two children with hemiparetic, spastic CP to determine if an 
intensive strength-training regimen would show evidence of neuroplastic changes.  In addition to 
the neurological changes documented, they found muscle size and motor function increased 
linearly (D. R. Lee et al., 2014). 
Although limited evidence exists to indicate treatments facilitate neural reorganization in 
patients with CP; sufficient evidence is available to warrant further investigations. As many 
factors influence the continuum from plasticity to vulnerability in this complex population, 
Anderson et al. (2011) suggests identification of interventions to target the developing brain and 
the minimization of secondary complications would be most valuable to inducing behavioral 
change in children who have experienced neurological insults.  
Treatments 
Physical Therapy Treatments. SLPs have included positioning and improved 
respiratory function to target articulatory outcomes in treatment without empirical evidence to 
support their choices. In fact, the shortage of research generated by researchers in 
communication disorders leaves SLPs with little evidence from which to select treatments to 
increase respiratory support for speech production in patients with motor impairments. Solomon 
and Charron (1998) suggested that SLPs seeking research regarding the management of 
breathing difficulties in children with CP refer to the physical therapy literature.  
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Early on, Massery (1991), PT, recounted a case study where a patient produced two 
syllables per breath during the initial assessment. After 2 months of physical therapy addressing 
chest wall development, the patient produced eight syllables per breath. Details of the treatment 
were not provided; however, results indicated that PT improved speech production. The results 
also support the present study’s hypothesis that manual therapy will increase rib cage ROM that 
will, in turn, lead to increased speech outcomes.  
Park, Park, Rha, Park,, & Park (2006) offer evidence to support that proper intervention 
in the early stages of development could resolve deviations in chest wall structure thus increasing 
respiratory function and decreasing fatigue.  Maintenance of soft tissue extensibility leads to 
reduced manifestation of disordered motor control and adaptive changes.  The prevention of 
contractures are traditionally managed by PTs using stretch (Katalinic et al., 2011).   
In the search for “best available evidence”, the SLP could benefit from accessing research 
in other disciplines.  In this case, research in PT (Jerome et al., 2013; Theis et al., 2013) yields 
results that indicate manual therapy may support increased speech outcomes. Practitioners and 
researchers alike should include research in other fields to support the development of EBPs in 
their own fields. Other disciplines may provide valuable contributions to the literature in another 
field; therefore, the following will discuss physical therapy treatments that may contribute to 
increased speech therapy outcomes.  
Neurodevelopmental Treatment. Beginning in the late 1970’s and early 1980’s the Bobath 
treatment protocol, later known as NDT, for children with CP and other motor impairments 
began holding a ridged adherence to normal developmental sequences to influence muscle tone 
and improve postural alignment by practicing specific therapeutic handling techniques (Mayston 
2001 a,b; Redstone 1991). As additional information and research became available in the area 
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of neuroscience, their approach evolved to comply with the understanding that the impaired 
systems could not follow the rigid neurodevelopment sequence that had been previously 
practiced. Also, functional tasks and active participation became vital components of the 
treatment in order to ensure carry over and generalization of skills (Butler & Darrah 2001).  
Researchers including Redstone (1991), DeGangi & Royeen (1994), and Mueller (1972) have 
used this approach to address the interactions and interdependence among the physiologic 
subsystems of the body.  Impaired sensorimotor components that are likely the result of nervous 
system damage include tone, postural control, reflexes, movement patterns, sensory/perception, 
and muscle memory (Butler & Darrah 2001).  Additionally, the treatment has been shown to 
combat the secondary effects of contractures and other deformities (Butler & Darrah 2001).   
The American Academy for CP and Developmental Medicine (AACPDM) plays an 
important role in influencing clinical practices by critically appraising current evidence regarding 
treatment techniques and protocols for the said population.  In an attempt to provide an unbiased 
review of the literature, it was concluded that there is currently an “absence of evidence” to 
support the use of NDT in children with CP and other developmental disabilities. The work’s 
intent was to encourage research in the area of this widely used treatment method (Butler & 
Darrah 2001).  
Stretch. Stretch is a widely used method to prevent and/or remediate contractures in 
patients with CP; however, there is currently inconsistent evidence regarding its efficacy 
(Katalinic et al., 2011; Pin et al., 2006; Riley & Van Dyke, 2012; Theis et al., 2013). Researchers 
have found evidence to support the immediate, transient effects of stretch on muscle length and 
ROM; however, long-term benefits continue to be questionable (Bovend'Eerdt et al., 2008; Riley 
& Van Dyke, 2012; Theis et al., 2013).   
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Several studies have obtained results that indicate stretch yields positive effects in 
children with spastic CP. One studied eight children ages 6-14 years old diagnosed with spastic 
CP. They received passive stretching, flexing of the ankle, in physical therapy. Stretches were 
applied 5 times for 20 seconds. The treatment resulted in increased muscle and tendon elongation 
and increased ROM. They surmised short-term muscle lengthening may lead to long- term 
adaptations over extended treatment in children with CP (Theis et al., 2013). Although passive 
stretch shows short-term benefits it is unclear if active stretch is needed to facilitate long-term 
results.  Riley and Van Dyke (2012) reported passive and active stretch resulted in reduced 
stiffness.  Transient effects of stretch persisted 1-2 hours; however, when stretched 15-60 
seconds daily, muscle changes were maintained for 24 hours. They documented reversion to the 
pre-stretch state occurred 2-3% daily after stretch protocol was withdrawn. Additionally, data 
suggested active stretch was required to change muscle fiber length, and the ROM of the 
individual was contingent on daily movement experiences. Given this evidence, possibly a 
combination of active and passive stretch would be most beneficial to children with CP. The 
duration of transient effects gives the SLP a window of time to work on utterance complexity 
and connected speech. This study gives guidance indicating the possibilities in modifications of 
treatment protocols and inclusion of stretch in the patients’ daily routines to possibly achieve 
speech and language results long-term. 
Continuing to narrow the scope of research, a systematic review of seven studies 
evaluated the effectiveness of passive stretching in children with CP (Pin et al., 2006).  This 
search yielded similar results as discussed previously. Evidence specific to physiotherapy for 
children with CP is limited, and contains substantial gaps; however, data support that stretching 
for longer durations improves ROM and reduces spasticity of muscles around targeted joints (Pin 
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et al., 2006). The authors suggested that clinicians include stretching activities and optimum 
positioning in daily routines to prolong the treatment effects. Pin and colleagues conclude that 
the body of research continues to be weak and the studies’ limitations make it difficult to make 
recommendations regarding current practices.  
In evaluating the evidence, the heterogeneity of the studies discussed should be 
considered.  The populations, number of participants, standardization of treatments, outcome 
measures, and inadequate designs make it difficult to draw definitive conclusions regarding the 
efficacy of stretch as a treatment for individuals with neuromuscular impairments (Bovend'Eerdt 
et al., 2008; Pin et al., 2006) because meta-analysis of the available studies is not possible. 
Although consistent findings regarding short-term benefits are available, current literature is 
unclear as to the long-term benefits of stretching on ROM, spasticity, muscle length, and 
functional changes in this population. Clarification would enable therapists to evaluate the 
benefits of incorporating manual treatment protocols into current treatment plans. Pressures from 
payers due to rising healthcare costs and treatment restrictions magnify the importance of 
streamlining treatments more than ever. 
Mary Massery (2012) offers a course titled “If You Can’t Breathe, You Can’t Function.” 
A portion of her protocol addresses phonation where she describes evaluation, positioning, 
manual techniques, verbal techniques, and carry over strategies for increasing breath support for 
phonation. The manual therapy techniques are of interest because they differ significantly than 
many speech pathology approaches. Percussion or vibration is used to provide sensory 
information regarding chest position, airflow, and motor planning to balance vocal fold tension 
and chest wall contractions. Diaphragm function is targeted using Proprioceptive Neuromuscular 
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Facilitation, controlled exhalation using vibration, and resistance to abdominals and intercostals 
(Massery 2012). 
Lastly, abdominal binding (trussing), a therapy approach used to address respiratory 
support, has little support in research with this population; however, indirect support is available 
when evaluating research with adults and physical therapy.  When using abdominal binding, the 
abdominal wall is held inward providing stability during movement. In doing so, the function of 
the diaphragm and rib cage is optimized producing longer utterance duration (Watson and Hixon 
2001). Hoit, Banzett, and Brown (2002) reported along with respiratory benefits, abdominal 
binding might reduce speech effort, assist neck muscle activation, glossopharyngeal breathing, 
and pharyngeal and buccal speech productions. In practice, this is done in a variety of ways such 
as belly binding, compression garments, and other devices. 
Research limitations. It is not only SLPs who have neglected to sufficiently address the 
treatment of children with severe motor impairments such as CP. The PT literature also describes 
the lack of research and the difficulties in completing research with the children with CP (Knox 
2002). Furthermore, expanding the scope of research from respiration to muscle changes in 
children with significant motor impairments yields similar results.  Knox, Evans, and Lloyd 
(2002) suggested the variability in current treatment approaches with ill-defined procedures and 
the absence of validated assessment measures make demonstrating efficacy in physical therapy 
challenging. A review of 37 studies for children in this population revealed the studies generally 
presented small sample sizes, were poorly controlled, and contained poor experimental design 
and analysis (Hur, 1995). Royeen and DeGangi (1992) cited the lack of rigorous research 
addressing the use of NDT. They reported of 19 studies evaluated a number have limited sample 
size, lacked suitable validated measures, and used poor research design.  Finally, Butler and 
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Darrah (2001) cited lack of discrete treatment dosages, nonspecific and variable treatment 
procedures, inconsistent treatment conditions, large range of therapists’ skill levels, and the 
complications of the patient’s growth and maturation. 
Speech Therapy Treatments. Often, the role of respiration in speech therapy treatments 
is overlooked in research. Pennington et al. (2006) indicates there is a “dearth” of research in 
speech-language pathology addressing respiratory function in patients with neuromuscular 
impairments.  The literature available has included positioning, regulation of respiratory function 
(e.g. Pennington, Smallman, & Farrier, 2006), and breathing exercises (e.g. Fox & Boliek, 2012) 
to target speech intelligibility. Others have chosen to address poor intelligibility by implementing 
augmentative, alternative, and supplementation communication strategies to provide cues to the 
listener (e.g. Hustad & Cahill, 2003; Hustad, Jones, & Dailey, 2003). Although there is some 
evidence to support each of these methods, they do not directly address the foundation of the 
speech problem, respiration due to ROM or muscle weakness of the chest wall.  
Lee Silverman Voice Treatment LOUD.  Lee Silverman Voice Treatment (LSVT) 
LOUD is a frequently utilized program intended to address respiratory and phonatory effort in 
patients with neuromuscular impairments. An important aspect of this treatment approach is that 
its efficacy is not influenced by the patient’s cognitive ability. The majority of research located 
addressed adults with Parkinson’s disease (e.g. Fox, Eberbach, Ramig, & Sapir, 2012). Kent 
(2000) warns against directly implementing adult research with children as the nature and 
mechanisms of childhood dysarthria differ significantly from that of adults. Another researcher 
points to adult systems being developed prior to the loss of function where children’s motor 
control systems continue to be developing. Additionally, the interaction of co-existing conditions 
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including cognition, phonological, and language further complicate the use of adult treatment 
protocols with children (Levy, 2014). 
A study of LSVT LOUD’s efficacy by Fox and Boliek (2012) followed five children, 
ages 5 to 7, with a medical diagnosis of spastic CP. LSVT LOUD procedures were followed 1 
hour, four days a week for four weeks. The protocol included sustaining vowels, maximum 
frequency range, and repetition of 10 functional phrases. Time was also spent progressing from 
production of single words to conversational speech. Two chi-square tests were used to assess 
the preferred speech samples in baseline versus posttest versus normal participants and baseline 
versus posttest versus follow up. For children with less output, incremental steps were taken 
based on baseline abilities.  Immediately following treatment, listeners preferred speech samples 
compared to those of the samples obtained during baseline in areas such as pitch, quality, 
loudness, and articulatory precision.  Maximum performance and acoustic measurements 
changed more consistently than the perceptual measures across participants. These results 
provide support for intensive voice treatment to improve facets of vocal functioning (C. M. Fox 
& Boliek, 2012). 
Speech Systems Intelligibility Treatment. Systematic research has been completed 
evaluating the efficacy of Speech Systems Intelligibility Treatment (Pennington, Miller, Robson, 
& Steen, 2010; Pennington et al., 2013; Pennington et al., 2006). The treatment protocol includes 
three to five 30 to 45 minute sessions of individual therapy for four to six weeks. In each 
treatment session, coordination of phonation onset with exhalation and spoken language tasks are 
practiced. Motor learning principles including frequent practice, random practice, and frequent 
feedback are implemented during skill acquisition. The use of reduced feedback, knowledge of 
results, and knowledge of performance are employed to facilitate skill retention. 
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 Results support the positive effects of motor learning activities. In one study, four of six 
children ages 10 to 18 years showed an immediate increase in single word intelligibility; 
however, significant increases were not documented in connected speech (Pennington et al. 
2006).  A second study looking at sixteen older children, 12-18 years old, utilizing the same 
protocol found increases in single word intelligibility with familiar listeners 14.7% and 15% with 
unfamiliar listeners. Additionally, increases were documented in connected speech to be 12.1% 
with familiar listeners and 15.9% with unfamiliar listeners (Pennington et al., 2010). Most 
recently, a study extended the age range to target younger children ages 5-11 years old. Results 
found speech intelligibility to increase after the protocol to 10.8% with familiar listeners and 
9.3% with unfamiliar listeners in single words. In connected speech intelligibility increased 9.4% 
with familiar listeners and 10.5% with unfamiliar listeners. Single word intelligibility in each of 
these studies was obtained using Children’s Speech Intelligibility Measure (Wilcox & Morris, 
1999). Each child repeated 50 words taken from a 200-word list. Listeners indicated the word 
they heard from 10 phonetically similar words. Each study also obtained speech samples to 
evaluate intelligibility in connected speech by asking the children to describe a sequence of three 
pictures.   
In addition, the authors used the Focus on the Outcomes of Communication Under Six 
(Thomas-Stonell, Oddson, Robertson, Walker, & Rosenbaum, 2012) to assess participation in 
communicative interactions. Results indicated a mean increase of 30.3 in the parent-reported 
measure and 28.25 in the teacher-reported measure (Pennington et al., 2013). 
Manual therapy.  Solomon & Charron (1998) completed a review of the literature 
regarding treatment of speech breathing in children with CP. After extensive research, they 
stated they were unable to locate efficacy studies regarding treatment influences on breathing for 
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speech. They concluded activities targeting muscle strength, endurance, muscle relaxation, 
passive stretch, balanced activity of muscle groups, and motor coordination were viable 
treatment options to research.  
A Phase 1, single-subject design study implemented a manual therapy protocol on a 4-
year-old ambulatory child diagnosed with CP (Varnado, Donovan, & Gonsoulin, 2014). 
Improvements in loudness measures were evidenced by a large effect size (d=4.0) from pre- to 
posttest and maintained a moderate effect (d=0.5) after three weeks of treatment withdrawal. 
Improvements in duration measures were evidenced by a large effect size (d=7.6) from pre- to 
posttest and fell to no effect (d=.05) after three weeks of treatment withdrawal. Additionally, 
increases were noted in both speech intelligibility (48% to 81%) and mean length of utterance 
(1.76 to 2.6) after three weeks of treatment withdrawal. Structural anatomical changes were 
visible by both the PT and SLP; however, measurements were not taken.  Additionally, parental 
and service provider reports indicated increased vocalizations and oral participation in center-
based and home activities. Results support the need for further research addressing the use of a 
manual therapy protocol in participants with severe motor impairments to influence speech 
outcomes, including sound pressure level and duration of phonation (Varnado et al., 2014). 
SPL and MPD are often used in voice assessments to determine neuromuscular control of 
voice features (Cielo & Cappellari, 2008; Rvachew, Hodge, & Ohberg, 2005). They are also 
used to track treatment progress in children with voice disorders (Rvachew et al., 2005). The 
majority of normative data available for these measures are for adults and children 6 and older.  
Normative data present in the literature for MPD contain large variability and often does 
not incorporate age, size, or height which influence lung volume (Kent, Kent, & Rosenbek, 
1987). Several studies disagree on specific age level expectations for MPD and chose to group 
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several age groups together. Kent, Kent, and Rosenbek (1987) and Cielo and Cappellari (2008) 
published results that provided age ranges for children 4 to 6 years old for phonation of /a/. For 
our purposes, only the means of MPD of /a/ for each age are included in Table 1 below. 
Table 1. Means of Maximum Phonation Time by Age 
Source 4 years 5 years 6 years 
Cielo & Cappellari (2008) 5.77* 7.16* 10.32* 
Kent, Kent, & Rosenbek (1987) 9.00* 10.00* 13.00* 
Note. *Measured in seconds (s). (Cielo & Cappellari, 2008; Kent et al., 1987). 
 
The literature examining normative data for SPL are inconsistent in both the methods and 
results; therefore, using SPL to compare to aged-matched peers is currently not possible. Each 
study utilizes different microphone to mouth distance, which prevent standardization across 
studies (Kent et al., 1987). This is also the case for other maximum performance measures (Kent 
et al., 1987); therefore, the use of the participant as his own control enables determination of 
therapy progress.  
In conclusion, many believe that the increasing numbers of clinical results and mounting 
evidence reveal the positive impact of focusing on breathing for speech intelligibility.  There are 
mixed reviews regarding the efficacy of treatment approaches to address respiration in children 
with severe motor deficits. However, the body of research as mentioned earlier is incomplete and 
insufficient.  Possible therapies include passive stretching, electrical stimulation, expiration with 
resistance, LSVT LOUD, NDT, posture modifications, speaking at the beginning exhalation, and 
marking stress, abdominal strengthening, torso-extension stretch, relaxation, abdominal binding, 
and balanced activity of muscle groups.  A wide range of intensities and durations has been 
documented to provide positive change. Therapy sessions ranged from 15 minutes to an hour, 
two to 4 times weekly. Two studies reported a parental education and home practice component.  
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Considerations for cognition, fatigue, other diagnoses, and seizure activity were inconsistently 
reported. 
Poor rib cage mobility, present in children with spastic CP, inhibits the production of 
audible and intelligible speech. This study aims to address the limitations of current research by 
assessing the efficacy of a treatment protocol that addresses structural constraints of the rib cage, 
while meeting the intensity restrictions imposed on practitioners by payers.  
Research Questions 
• What are the treatment effects of a manual therapy protocol on speech outcomes, 
intensity (dB SPL) and duration (s), in children diagnosed with spastic CP? 
• What are the effects of the protocol on functional communication (speech intelligibility 
and SBU)? 
• What are the effects of the protocol on the mobility of the rib cage (chest expansion) and 
on abdominal protrusion? 
Hypotheses 
Current literature led to the following hypotheses:  
• Accelerating trajectory change of sound pressure level (dB SPL) and duration of 
phonation (s) will occur upon initiation of manual therapy protocol.  Upon withdrawal of 
the treatment, the trajectory of the primary outcome measures will return toward baseline 
measures. 
• Both speech intelligibility measures and SBU will increase during each treatment phase 
and decline during each withdrawal phase. 
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• The difference in rib cage circumference at each location will increase after treatment is 
initiated and decrease upon withdrawal. Abdominal protrusion will decrease after 
treatment is initiated and increase upon treatment withdrawal. 
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CHAPTER 3. 
METHODS 
Design 
The following, Phase 2 study was a partial replication of Varnado, Donovan, and 
Gonsoulin (2014) that utilized a withdrawal, single-subject (ABAB) experimental design, across 
participants. This design was chosen for its high degree of experimental control and the 
possibility of eliciting multiple demonstrations of effect.  Byiers (2012) indicated this design is 
the strongest design to demonstrate treatment effect. Ethical considerations regarding the 
withdrawal of an effective treatment should be noted. The design concluded with a treatment 
phase and the ongoing therapist was trained to continue the treatment protocol. The Risk of Bias 
in N-of-1 Trials (RoBiNT) Scale (Tate et al., 2013), an instrument designed to assess quality in 
single-case experimental designs, was used to ensure adequate measures are taken to achieve 
maximum research design quality and experimental control. See Appendix A for a list of the 
scale’s items and Table 1 for an outline of the design phases. 
Before initiation of subject selection, acquisition of informed consent, child assent, 
collection of data, and implementation of treatment protocol, Louisiana State University’s 
Institutional Review Board for the protection of human subjects approved the study proposal (see 
Appendix B). 
Participants 
  Five participants, ages 4-6 years, were selected from the population of children with 
spastic CP in local educational settings. No compensation was provided to study participants for 
involvement in this study. Parents provided informed consent (see Appendix C) prior to initiation 
of study procedures. 
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 Inclusion criteria included: adequate hearing evidenced by ability to participate in testing, 
aided or unaided; ≥ Level 2 on the Gross Motor Function Classification System (Palisano et al., 
2012); medical diagnosis of spastic CP. Exclusion criteria included: previous surgical treatment 
or currently medicated for spasticity; active seizure activity, uncontrolled asthma, significant 
scoliosis as to effect respiratory function, additional medical concern that would prevent 
application of treatment protocol; inability to follow simple directions to complete the treatment 
as reported by ongoing therapists. 
To further describe the participants, the Clinical Evaluation of Language Fundamentals 
(CELF) Preschool -2 was administered prior to data collection (Wiig, Secord, & Semel, 2004). 
Additionally, each participant was classified utilizing the Communication Function 
Classification System (CFCS) for Individuals with CP (Hidecker et al., 2011) by the PI. See 
descriptions of each level in Appendix F.  
Treatment Setting 
 Treatment took place in standard therapy rooms and classrooms with minimal 
distractions. Distractors were removed from the child’s view. Participants watched a video of 
their choosing during the administration of the protocol to ensure compliance and reinforce 
participation. At the conclusion of each session the participant was allowed to choose a prize for 
participation. Items were chosen based on each participant’s cognitive status, preferences, and 
motor abilities. 
Investigators 
The investigator, a certified SLP, with 13 years of experience in pediatric speech and 
language rehabilitation, completed the protocol procedures, obtained chest and abdominal 
measurements, and collected speech samples.  Speech pathology undergraduate students blind to 
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the study’s purpose and phase assisted the investigator. Following training from the investigator, 
the assistants collected intensity and duration data to control for investigator bias. To ensure 
measurement fidelity, the investigator observed 100% of the sessions to ensure procedures were 
followed.  To ensure treatment fidelity, the assistants observed 50% of the treatment sessions. A 
binary choice (+/-) checklist was completed indicating compliance with procedures for both 
measurement and treatment fidelity checks (see Appendix G and H). Three additional speech 
pathology undergraduate students unfamiliar with the participants and motor speech disorders 
transcribed the speech sample recordings as described below for later analysis. 
Equipment 
 Speech sample recordings were collected using an Olympus Imaging Corporation DS-20 
digital voice recorder. Digital files were saved to a Dell desktop computer. Duration and SBU 
data were analyzed using PRAAT computer software (Boersma & Weenick, 2002) following 
procedures described by van Lieshout (2003). The procedure includes making a speech object 
from the long sound file and using both the spectrogram representation and the corresponding 
audio files to accurately measure each variable. Furthermore, the Audacity (2015) software 
version 3.0 was used to edit the sound files for intelligibility transcriptions and counting of SBU.  
A Larson Davis DSP82 (Participants 1 and 2) and Extech Instruments 407732 
(Participants 3, 4, and 5) sound pressure level meters with fast, C weighting were used to 
measure the intensity of the acoustic signal. The microphone was held six inches from the 
participant’s mouth. This distance was maintained by adding a six-inch extension that did not 
obstruct the microphone. Each device was calibrated to conform to American National Standards 
Institute (ANSI) standards prior to data collection. Lastly, one standard tape measure was used to 
take all chest and abdomen circumference measurements.  
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Procedures 
 Baseline Phase (A1). Five measurements of SPL and MPD of /a/ were collected for five 
sessions. During this phase, steps were taken to help the participant understand the directions. 
After the prompt and model were provided, the research assistant and the participant practiced 
the vocalization together. If measurements were within 2 standard deviations of the mean and the 
data trajectory was stable or decelerating, the participant began the treatment phase. If the stable 
baseline measurements were not present, the baseline phase would have been extended until 
criteria were met. Extension of baseline measures to achieve stability was not needed in these 
cases. 
Treatment Phases (B1 and B2).  The treatment was applied for five sessions for 15 
minutes. It was the goal to complete each phase in a given week; however, if the data or absences 
altered the number of sessions in a given week, the number of sessions served as the criteria for 
moving to the next phase. Primary outcome measures were collected during each session. All 
other treatments were continued at recommended dosages, due to the medical needs of the 
participants in the targeted population and to address any possibility of treatment interaction.  
Tasks were counter-balanced as to prevent order effect.  See Appendix I for randomization of 
tasks for each participant. The treatment protocol included: 
1. Anterior Intercostal Stretch:  The patient sat facing away from the therapist 
straddling a large bolster. The therapist reached around the patient and using the 
pads of the middle fingers applied pressure to the intercostals in first rib space 
beginning at sternum and moving laterally.  Pressure duration was sufficient to 
achieve muscle release. The stretch was repeated in each rib space moving down 
the chest wall. 
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2. Posterior Intercostal Stretch:  The patient sat facing the therapist straddling 
therapist’s torso on a large bolster.  The patient rested into the therapist’s hands, 
leaning back. The therapist reached around the patient and using the pads of the 
middle fingers applied pressure to intercostals in first rib space beginning at 
vertebrae and moving laterally. Pressure and duration were sufficient to achieve 
muscle release. The stretch was repeated in each rib space moving down the 
posterior rib cage. 
3. Lateral Intercostal Stretch:  The patient sat away from the therapist on the bolster.  
The therapist formed an “L”-shape with pointer finger and thumb and placing the 
angle formed in highest rib space that could be reached on the lateral chest wall 
under the armpit.  The therapist rolled the patient into the angle formed by the 
hand. The participant’s opposite arm was raised by the same side ear.  The 
participant was instructed to “Reach.” in the direction of the stretch. Pressure and 
duration were sufficient to achieve muscle release.  The stretch was repeated in 
each rib space moving down the rib cage.  This series was completed bilaterally. 
4. Bolster Stretch:  Patient lied on their side across a large bolster. Therapist formed 
an “L”-shape with the pointer finger and thumb and placed the angle formed in 
highest rib space that could be reached on the lateral chest wall under the armpit. 
The participant’s opposite arm was raised by the same side ear.  The participant 
was instructed to “Reach.” in the direction of the stretch.  Pressure and duration 
were sufficient to achieve muscle release.  The stretch was repeated in each rib 
space moving down the rib cage. This series was completed bilaterally. 
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5. Intercostal Percussion:  The patient sat facing away from the therapist straddling a 
large bolster.  The therapist formed an “L”-shape with the pointer finger and 
thumb and placed the angle formed in the highest rib space that could be reached 
on the lateral chest wall under the armpit on both sides.  Therapist prompted and 
modeled, “Take a deep breath in, and push all the air out.”  As the patient exhales, 
therapist shook and pulled down on the rib space until exhale is complete.  
Percussion was repeated in each rib space moving down the rib cage.  
To ensure treatment fidelity, two undergraduate students observed 50% of the treatment 
sessions. A binary choice (+/-) checklist was completed indicating compliance with procedures 
for each task. A percentage was calculated to quantify the degree of compliance with task 
procedures. 
Withdrawal Phase (A2).  A sham treatment was implemented for five sessions for 15 
minutes each day. Primary outcome measures were collected during the five sessions. All other 
treatments continued at recommended dosage, due to the medical needs of the participants in the 
targeted population and to address any possibility of treatment interaction.  Tasks were counter-
balanced as to prevent order effect.  For participants who exhibit upper limb paralysis or paresis, 
the therapist augmented the stretches. The sham treatment included:  
1. Lateral Neck Stretch: The patient sat in an upright position. Therapist prompted 
and modeled, “tilt your head to the left/right”. Each stretch was held for 20 
seconds and completed bilaterally 5 times. 
2. Posterior Neck Stretch: The patient sat in an upright position. Therapist 
prompted and modeled, “bring your chin down toward your chest”. Each 
stretch was held for 20 seconds 5 times. 
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3. Forearm Stretch: The patient was seated in an upright position. Therapist 
prompted and modeled, “hold your arm out in front of your body, turn the palm 
of your hand toward the floor, and hold your fingers with the other hand.” Each 
stretch was held for 20 seconds and completed bilaterally 5 times. 
4. Wrist Stretch: The patient sat in an upright position. Therapist prompted and 
modeled, “hold your arm out in front of your body, turn the palm of your hand 
toward the ceiling, and hold your fingers with your other hand”. Each stretch 
was held for 20 seconds and completed bilaterally 5 times. 
Data Collection 
Primary outcomes. Data collection of primary outcome measures occurred during the 
baseline phase (A1) and immediately after each treatment session. Measurements of dependent 
variables were collected utilizing the following procedures given the prompt, “Say “ah” as loud 
as you can and as long as you can.” A model was also provided. 
1. Sound pressure level:  the sound level meter was held 6 inches from the participants’ 
mouths as the participant responds to the prompt.  Output was measured and recorded 
in decibels (dB SPL). 
2. MPD of /a/:  the digitally recorded data were analyzed in PRAAT (Boersma & 
Weenick, 2002) and the number of seconds of phonation was measured and  
documented in seconds (s). Duration measurement procedures followed that 
described in van Lieshout (2003). 
Secondary Outcome Measures. Secondary outcomes were administered at baseline and 
at the conclusion of each phase.  Ten sentences randomly generated from the list of 5 word 
sentences from the Assessment for Intelligibility of Dysarthric Speech (Yorkston & Beukelman, 
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1981) were used for each measurement. This instrument’s high validity and reliability was 
believed to provide accurate representation of the participants’ abilities. Procedures of the 
assessment were otherwise followed to obtain the speech samples. Research assistants unfamiliar 
with the participants analyzed the recordings at a later date. 
1. Speech intelligibility:  Three speech-pathology students who were unfamiliar 
with the participants and have had no clinical experience with motor speech 
disorders transcribed the recorded samples.  They were instructed to listen to 
each utterance two times then transcribe the utterance orthographically. The 
number of correct words was divided by the total number of words to obtain a 
percent speech intelligibility score according to methods described in the 
Assessment for Intelligibility of Dysarthric Speech (Yorkston & Beukelman, 
1981). The listeners were blinded to the phase of the study. 
2. SBU: The recordings used for intelligibility analysis were further analyzed to 
determine the mean number of SBUs for each sample. The number of 
syllables were counted and recorded. The mean was calculated by dividing the 
sum of the number of syllables in each utterance by the total number of 
utterances in each phase. 
3. Chest expansion: Procedures defined by Jerome, Passi, and Koli (2013) were 
followed to document chest expansion. Circumference measurements were be taken 
at the maximum inspiratory and expiratory positions of the rib cage at three locations: 
at the axilla, nipple, and the tip of the xyphoid process. Three attempts were averaged 
for each position. 
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4. Abdominal Circumference: The circumference of the abdomen was taken at the level 
of the waist. The participant stood upright if physically possible. For participants who 
were unable to stand or access a stander, the measurement was taken in their typical 
seating apparatus (i.e. wheelchair). 
Table 2. Design Phases 
Phase Baseline (A1) Treatment (B1) Sham (A2) Treatment (B2) 
Duration 1 Week 
 
1 Week 
 
1 Week 
 
1Week 
Action No Treatment Manual Therapy Sham Stretch Manual Therapy 
Daily 
Measures 
Intensity 
Duration 
Intensity 
Duration 
Intensity 
Duration 
Intensity 
Duration 
One Time 
Measure 
Intelligibility 
SBU 
Chest Expansion 
Abdominal 
Protrusion 
Intelligibility 
SBU 
Chest Expansion 
Abdominal 
Protrusion 
Intelligibility 
SBU 
Chest Expansion 
Abdominal 
Protrusion 
Intelligibility 
SBU 
Chest Expansion 
Abdominal 
Protrusion 
Data Analysis 
Three undergraduate speech therapy students unfamiliar with the study’s purpose visually 
inspected graphed data. Trend, level, and variability of the data in a given phase and comparisons 
of the adjacent phases were evaluated to locate demonstrations of effect (Kratochwill et al., 
2010; McReynolds & Kearns, 1983). The immediacy of the effect, % of NOD data, and 
consistency of the data patterns across phases were documented (Kratochwill et al., 2010; Tate et 
al., 2013). Effect sizes were calculated using accepted methodology by dividing standard mean 
difference by the standard deviation (Busk & Serlin, 1992).  Because no treatment studies have 
been reported in this area, data were interpreted using Cohen’s d descriptions (0.2 indicates small 
effect, 0.5 indicates moderate effect, 0.8 indicates large effect) (Cohen, 1988).  The raw data are 
included in Appendices J through N to as recommended by Durlak (2009) preventing the loss of 
information and allowing the research consumer to evaluate the results in context.  This practice 
will further assist in the selection of the most appropriate treatment for patients. The secondary 
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outcome measures of speech intelligibility, SBU, and chest expansion were analyzed 
descriptively. 
Treatment and Measurement Fidelity 
 Undergraduate students through observation completed a checklist of indicators for each 
task to ensure treatment fidelity. The observer designated “COMPLY” or “DID NOT COMPLY” 
for 5 indicators for each task. For each participant, 5 of 10 treatment sessions were observed. 
This exceeds the 20 percent required for each participant deemed necessary by Kratochwill et. al. 
(2010).  100% compliance was maintained for each participant.  
 To ensure measurement fidelity of SPL measurements, undergraduate research assistants 
unfamiliar with the study’s phase or purpose collected the primary outcome measurements. The 
PI was present to ensure all procedures were followed. A checklist of five indicators for the 
measurement was completed for 5 of 20 sessions, which equates to 20 percent of data collection 
sessions as suggested by Kratzchwill et al. (2010). The MPD was recorded and analyzed later 
utilizing PRAAT software to extract duration of measures in seconds (s). Two undergraduate 
research assistants without knowledge of treatment phase checked each measurement. Pearson 
product-moment correlations were computed to determine interrater reliability of MPD 
measurements. SPSS version 22 was used to calculate correlation. 
 As noted earlier, three speech-pathology students who were unfamiliar with the 
participants and have had no clinical experience with motor speech disorders transcribed the 
recorded speech samples.  They were instructed to listen to each utterance two times then 
transcribe the utterance orthographically. The measurements were then averaged for a single 
percent intelligibility score. SPSS version 22 was used to calculate correlations. Additionally, a 
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research assistant double-checked 20% of SBU counts. Percentage of agreement was reported. 
Lastly, all data entry was double-checked for accuracy. 
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CHAPTER 4. 
RESULTS 
Sample Demographics 
 Five participants ages 4 to 6 years old participated in the study. Demographic information 
for each participant is summarized in Table 2 below. Descriptions for GMFS (Palisano et al., 
2012) and CFCS (Hidecker et al., 2011) are located in Appendices E and F.  
Table 3. Participant Characteristics 
Participant Age Gender GMFS 
Level 
CFCS 
Level 
Expressive 
Language* 
Receptive 
Language* 
1 4 M V III 63 75 
2 4 F IV V 53 55 
3 4 F II III 81 75 
4 5 F V II 59 55 
5 6 F II II 83 77 
Note. GMFS = Gross Motor Function Scale (Palisano et al., 2012); CFCS = Communicative 
Function Classification System (Hidecker et al., 2011); *CELF-Preschool (2nd ed.) (Wiig et al., 
2004), Standard scores with M = 100 and s.d.=15. 
 
Participant 1. Upon visual inspection of the graphed data in Figure 3 depicting sound 
pressure level measurements, 3 of 3 undergraduates unfamiliar with the purpose or procedures of 
the study identified a decelerating baseline (A1), accelerating trajectory in the first treatment 
phase (B1), decelerating/stable trajectory in the withdrawal phase (A2), and an accelerating 
trajectory in the second treatment phase (B2). The trend, level, variability, immediacy of effect, 
and % of NOD for each phase is reported in Table 4. Effect sizes, also reported in Table 4, 
compared A1/B1 phases and A2/B2 phases. The data reveal 3 of 3 demonstrations of effect. The 
raw data for this participant are located in Appendix J for your reference.  
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Figure 3. Means of three measures of sound pressure level obtained at the conclusion of each 
treatment session.  
 
Table 4. Sound Pressure Level Analysis for Participant 1 
Phase Trend Level Variability Immediacy of 
Effect 
%of NOD Effect 
Size 
A1 -1.286 79.09 3.06    
B1 1.202* 87.17* 3.15* 1st data point* 80%* 2.64* 
A2 -.720* 79.48* 2.10* 1st data point* 80%*  
B2 1.940* 88.82* 3.57* 1st data point* 80%* 4.44* 
Note. *Indicates demonstration of effect.  
Visual inspection of the graphed data in Figure 4 depicting MPD of /a/ measurements 
indicated 3 of 3 undergraduates unfamiliar with the purpose or procedures of the study reported a 
descending baseline (A1), flat trajectory in the first treatment phase (B1), flat trajectory in the 
withdrawal phase (A2), and an accelerating trajectory in the second treatment phase (B2). The 
trend, level, variability, immediacy of effect, % of NOD, and consistency of data for each phase 
is reported in Table 5. Effect size calculations comparing A1/B1 and A2/B2 phases are reported in 
Table 5. The data reveals 1 of 3 demonstrations of effect. The raw data for this participant are 
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located in Appendix J for your reference. Table 6 depicts the means for the secondary outcome 
measures for Participant 1.  
 
Figure 4. Means of three measures of duration obtained at the conclusion of each treatment 
session. 
 
Table 5. Duration Analysis for Participant 1 
Phase Trend Level Variability Immediacy 
of Effect 
% of NOD Effect Size 
A1 -.02 .34 .04    
B1 -.04 .26 .09 none 20% -2.00 
A2 -.02 .27 .04 none 0%  
B2 .47* 1.88* .97* 1 data point* 100%* 1.64* 
Note. *Indicates demonstration of effect.  
 
Table 6. Secondary Outcome Measures for Participant 1 
Phase Intelligibility* SBU 𝑋Axilla** 𝑋 Nipple** 𝑋 Xyphoid** Abdomen** 
A1 4.67 1.0 .42 .40 .58 21.0 
B1 12.67 2.9 .71 .98 .94 17.5 
A2 12.67 1.8 .52 .65 .42 21.5 
B2 16.67 2.3 .83 .77 .85 20.0 
Note. *Measured in %; **Measured in inches. 
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Participant 2. Upon visual inspection of the graphed data in Figure 5, 3 of 3 raters 
reported a decelerating trajectory of baseline measures (A1), accelerating trajectory in the first 
treatment phase (B1), decelerating/stable trajectory in the withdrawal phase (A2), and an 
accelerating trajectory in the second treatment phase (B2). The trend, level, variability, 
immediacy of effect, % of NOD, and consistency of data for each phase is reported in Table 7. 
Effect size calculations comparing A1/B1 phases and A2/B2 phases are included in Table 7. The 
data reveal 3 of 3 demonstrations of effect. The raw data for this participant are located in 
Appendix K for your reference.  
 
Figure 5. Means of three measures of sound pressure level obtained at the conclusion of each 
treatment session. 
Visual inspection of the graphed data in Figure 6 depicting MPD of /a/ measurements 
indicated 3 of 3 undergraduates unfamiliar with the purpose or procedures of the study reported a 
decelerating baseline (A1), accelerating trajectory in the first treatment phase (B1), accelerating 
trajectory in the withdrawal phase (A2), and an accelerating trajectory in the second treatment 
phase (B2). The trend, level, variability, immediacy of effect, % of NOD, and consistency of data 
for each phase is reported in Table 8 each supporting the presence of a positive treatment effect. 
Effect size calculations comparing A1/B1 phases and A2/B2 phases are also located in Table 8. 
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The data reveal 3 of 3 demonstrations of effect. The raw data for this participant are located in 
Appendix K for your reference. Table 9 depicts the means for the secondary outcome measures 
for Participant 2.  
Table 7. Sound Pressure Level Analysis for Participant 2 
Phase Trend Level Variability Immediacy of 
Effect 
% of NOD Effect Size 
A1 -1.12 81.31 2.33    
B1 .70* 90.86* 2.17* 1st data point* 100%* 4.10 
A2 -.15* 79.46* 6.26 1st data point* 100%*  
B2 .14* 89.73* 7.83* 1st data point* 60%* 1.64* 
Note. *Indicates demonstration of effect.  
 
Figure 6. Means of three measures of duration obtained at the conclusion of each treatment 
session. 
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Table 8. Duration Analysis for Participant 2 
Phase Trend Level Variability Immediacy of 
Effect 
% of NOD Effect Size 
A1 -.15 1.02 .22    
B1 -.01* 1.12* .29* 2 data points* 20% .42* 
A2 -.03 .92* .12* 1 data point* 20%  
B2 .42* 1.14* .10* 1 data point* 100%* 3.98* 
Note. *Indicates demonstration of effect.  
Table 9. Secondary Outcome Measures for Participant 2 
Phase Intelligibility* SBU 𝑋Axilla** 𝑋 Nipple** 𝑋 Xyphoid** Abdomen** 
A1 1.3 3.4 .21 .52 .23 19.0 
B1 0.0 4.2 .81 .69 1.25 19.5 
A2 0.0 3.2 .58 .38 .54 19.0 
B2 0.0 5.0 1.04 1.05 1.19 19.0 
Note. *Measured in %; ** Measured in inches. 
 
Participant 3. Upon visual inspection of the graphed data in Figure 7, 3 of 3 raters 
reported a stable baseline (A1), accelerating trajectory in the first treatment phase (B1), 
accelerating trajectory in the withdrawal phase (A2), and an accelerating trajectory in the second 
treatment phase (B2). The trend, level, variability, immediacy of effect, % of NOD, and 
consistency of data for each phase is reported in Table 10 each supporting the presence of a 
positive treatment effect. Effect size calculations comparing A1/B1 phases and A2/B2 phases 
indicate positive treatment effect. The data reveals 3 of 3 demonstrations of effect. The raw data 
for this participant are located in Appendix L for your reference.  
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Figure 7. Means of three measures of sound pressure level obtained at the conclusion of each 
treatment session.  
 
Table 10. Sound Pressure Level Analysis for Participant 3 
Phase Trend Level Variability Immediacy of 
Effect 
% of NOD Effect Size 
A1 .84 84.87 1.16 
 
   
B1 .36* 91.06* 1.31* 1 data point* 100%* 5.35* 
A2 .61* 83.91* 1.98* 1 data point* 100%*  
B2 .78* 98.13* 2.88* 1 data point* 100%* 7.17* 
 
Visual inspection of the graphed data in Figure 8 depicting MPD of /a/ measurements 
indicated 2 of 3 raters reported a stable/decelerating baseline (A1), decelerating trajectory in the 
first treatment phase (B1), decelerating trajectory in the withdrawal phase (A2), and a flat 
trajectory in the second treatment phase (B2). 1 of 3 undergraduates identified a flat trajectory in 
the first treatment phase (B1) and agreed with the other judges of phases 1, 3, and 4.  The trend, 
level, variability, immediacy of effect, % of NOD, and consistency of data for each phase is 
reported in Table 11. Effect size calculations comparing A1/B1 phases and A2/B2 phases are also 
reported in Table 11. The data reveals 2 of 3 demonstrations of effect. The raw data for this 
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participant are located in Appendix L for your reference. Table 12 depicts the means for the 
secondary outcome measures for Participant 3.  
 
Figure 8. Means of three measures of duration obtained at the conclusion of each treatment 
session. 
 
 
Table 11. Duration Analysis for Participant 3 
Phase Trend Level Variability Immediacy of 
Effect 
% of NOD Effect Size 
A1 -.15 1.02 .24    
B1 .01* 1.12* .29* 2 data points* 20% .22* 
A2 -.08* .78* .17* 2 data points* 80%*  
B2 -.02 .77 .17 none 0% -.06 
Note. *Indicates demonstration of effect.  
Table 12. Secondary Outcome Measures for Participant 3 
Phase Intelligibility* SBU 𝑋Axilla** 𝑋 Nipple** 𝑋 Xyphoid** Abdomen** 
A1 14.00 3.8 .31 .33 .54 20 
B1 15.67 4.2 .90 .75 1.02 19 
A2 8.33 3.5 .42 .33 .56 20 
B2 7.00 4.1 .58 .81 .62 20 
Note. * Measured in %; **Measured in inches. 
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Participant 4. Upon visual inspection of the graphed data in Figure 9, 3 of 3 raters 
reported stable baseline (A1), decelerating trajectory in the first treatment phase (B1), 
accelerating trajectory in the withdrawal phase (A2), and an accelerating trajectory in the second 
treatment phase (B2). The trend, level, variability, immediacy of effect, % of NOD, and 
consistency of data for each phase are reported in Table 13. Effect size calculations comparing 
A1/B1 phases and A2/B2 phases are also reported in Table 13. The data reveal 3 of 3 
demonstrations of effect. The raw data for this participant are located in Appendix M for your 
reference.  
 
Figure 9. Means of three measures of sound pressure level obtained at the conclusion of each 
treatment session.  
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Table 13. Sound Pressure Level Analysis for Participant 4 
Phase Trend Level Variability Immediacy of 
Effect 
% of NOD Effect Size 
A1 .00 77.75 5.24    
B1 -.37 87.34* 1.37* 1 data point* 100%* 1.83* 
A2 .65* 79.31* 2.52* 1 data point* 100%*  
B2 1.37* 89.62* 3.24* 1 data point* 100%* 4.07* 
Note. *Indicate treatment effect. 
 
 
Figure 10. Means of three measures of duration obtained at the conclusion of each treatment 
session. 
 
Visual inspection of the graphed data in Figure 10 depicting MPD of /a/ measurements 
indicated 3 of 3 raters reported a stable baseline (A1), decelerating trajectory in the first treatment 
phase (B1), decelerating trajectory in the withdrawal phase (A2), and an accelerating trajectory in 
the second treatment phase (B2). The trend, level, variability, immediacy of effect, % of NOD, 
and consistency of data for each phase is reported in Table 14. Effect size calculations comparing 
A1/B1 phases and A2/B2 phases are also reported in Table 14. The data reveal 0 of 3 
demonstrations of effect. The raw data for this participant are located in Appendix L for your 
reference. Table 15 depicts the means for the secondary outcome measures for Participant 4.  
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Table 14. Analysis of Duration for Participant 4 
Phase Trend Level Variability Immediacy of 
Effect 
% of NOD Effect Size 
A1 .13 1.57 .56    
B1 -.14 1.59 .70 3 data points* 20% .02 
A2 -.16 1.80 .44 none 0%  
B2 .13* 1.05 .30 none 100% -1.43 
Note. *Indicates demonstration of effect.  
Table 15. Secondary Outcome Measures for Participant 4 
Phase Intelligibility* SBU 𝑋Axilla** 𝑋 Nipple** 𝑋 Xyphoid** Abdomen** 
A1 11.33 6 .17 .29 .31 21 
B1 31.00 6.3 .67 .88 .75 20 
A2 17.67 6.1 .19 .29 .33 21 
B2 16.67 5.7 1.10 .79 .94 19 
Note. *Measured in %; **Measured in inches. 
Participant 5. Upon visual inspection of the graphed data in Figure 11, 3 of 3 
undergraduates unfamiliar with the purpose or procedures of the study reported a stabilized 
baseline, flat trajectory in the first treatment phase (B1), decelerating trajectory in the withdrawal 
phase (A2), and a decelerating trajectory in the second treatment phase (B2). The trend, level, 
variability, immediacy of effect, % of NOD, and consistency of data for each phase is reported in 
Table 16. Effect size calculations comparing A1/B1 phases and A2/B2 phases are also located in 
Table 16. The data reveal 3 of 3 demonstrations of effect. The raw data for this participant are 
located in Appendix N for your reference. 
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Figure 11. Means of three measures of sound pressure level obtained at the conclusion of each 
treatment session.  
 
Table 16. Analysis for SPL for Participant 5 
Phase Trend Level Variability Immediacy of 
Effect 
% of NOD Effect Size 
A1 .12 89.14 6.60    
B1 -.03 97.85* 1.74* 1 data point* 100%* 1.32* 
A2 -.80 94.82* 1.63* 1 data point* 80%*  
B2 -1.67 102.10
* 
3.11* 1 data point* 100%* 4.46* 
Note. *Indicates demonstration of effect.  
Visual inspection of the graphed data in Figure 12 depicting MPD of /a/ measurements 
indicated 3 of 3 raters reported a stable baseline (A1), a decelerating trajectory in the first 
treatment phase (B1), accelerating trajectory in the withdrawal phase (A2), and a decelerating 
trajectory in the second treatment phase (B2). The trend, level, variability, immediacy of effect, 
% of NOD, and consistency of data for each phase is reported in Table 17. Effect size 
calculations comparing A1/B1 phases and A2/B2 phases are also located in Table 17. The data 
reveal 3 of 3 demonstrations of effect. The raw data for this participant are located in Appendix 
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N for your reference. Table 18 depicts the means for the secondary outcome measures for 
Participant 5.  
 
Figure 12. Means of three measures of duration obtained at the conclusion of each treatment 
session. 
 
Table 17. Duration Analysis for Participant 5 
Phase Trend Level Variability Immediacy of 
Effect 
% of NOD Effect Size 
A1 .50 3.14 1.83    
B1 -2.85 5.72* 5.53 1 data point* 40% .47* 
A2 .79* 3.59* 1.71 none 0%  
B2 -.95 9.15* 1.69* 1 data point* 80%* 3.24* 
Note. *Indicates demonstration of effect 
 
Table 18. Secondary Outcome Measures for Participant 5 
Phase Intelligibility* SBU 𝑋Axilla** 𝑋 Nipple** 𝑋 Xyphoid** Abdomen** 
A1 26.67 5.0 .83 .81 .42 19.00 
B1 45.00 6.0 .75 .83 .52 19.00 
A2 34.67 2.5 .56 .47 .44 19.63 
B2 11.33 6.5 .94 .85 1.65 19.00 
Note. *Measured in %; **Measured in inches. 
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Treatment and Measurement Fidelity 
Undergraduate research assistants completed treatment fidelity checklists in 20% of 
treatment sessions. Five indicators for each task were judged. Treatment sessions observed were 
100% in compliance with protocol procedures. Similarly, the PI completed measurement fidelity 
checklists for 20% of sessions. 100% compliance was maintained for the intensity measurement. 
Reliability Measures 
The primary investigator and two research assistants extracted MPD measurements from 
the speech sample recordings. Pearson product-moment correlations were computed using SPSS 
version 22.  All correlations among the investigators and research assistants were statistically 
significant (p < .001). Strong positive correlations (r > .90) were found between each pair of 
judges. The following correlations were obtained: Judges 1 and 2 (r =.99), Judges 1 and 3 (r 
=.98), and Judges 2 and 3 (r =.99). 
 
Question 1 
What are the treatment effects of a manual therapy protocol on speech outcomes, intensity (dB) 
and duration (s), in children diagnosed with spastic CP? 
In examining the data across participants, 15 of 15 demonstrations of effect and 0 
demonstrations of non-effect were located for SPL, and 8 of 15 demonstrations of effect for 
MPD of /a/ were located. This data support a positive effect on speech outcome measures of SPL 
given a manual therapy treatment addressing spasticity. The inconsistency of MPD data provided 
minimal support the presence of a treatment effect given one week of treatment. The immediacy 
of each effect, % of NOD and consistency of data patterns across each phase for each participant 
further strengthen the ability to make causal inference that there was a treatment effect on SPL 
given the manual therapy protocol. Those measures for MPD showed inconsistent evidence of a 
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treatment effect. Effect sizes for SPL ranged from 1.32 to 7.17 also indicating a treatment effect, 
whereas, effect sizes for MPD ranged from -2 to 3.98 indicating strongly negative to strongly 
positive treatment effect. The inconsistences of the MPD data are further discussed below. 
Question 2 
What are effects of the protocol on functional communication (speech intelligibility and SBU)? 
Speech intelligibility across participants improved in 5 of 10 treatment phases and 
stabilized or decreased during 3 of 5 withdrawal phases. Table 19 depicts the mean intelligibility 
score obtained from 10, 5-word utterances examined by 3 listeners unfamiliar with motor speech 
disorders or the participant across participants at the conclusion of each phase.  
SBU improved in 9 of 10 treatment phases and stabilized or decreased in 5 of 5 
withdrawal phases. Table 20 describes the number of SBU across participants at the conclusion 
of each phase. The measurements were extracted from the sentence prompts used in the 
intelligibility measurements using PRAAT software (Boersma & Weenick, 2002). 
Question 3 
What are the effects of the protocol on the mobility of the rib cage (chest expansion) and on 
abdominal protrusion? 
Measurements of rib cage circumference were used to determine whether the treatment 
had an effect on rib cage mobility. Results indicated that the difference in chest wall 
circumference from maximum inhalation to maximum exhalation  increased during manual 
therapy treatment phases and declined during withdrawal phases. For each data point, three 
measurements were taken and averaged at the level of the axilla, nipple, and xyphoid process. 
The differences are reported in Table 21.  To determine whether abdominal protrusion was 
reduced, the abdominal circumference at the level of the waist of each participant was measured 
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at the end of each phase. The measurements decreased during treatment as hypothesized in 6 of 
10 opportunities and returned toward baseline during the withdrawal phase in 4 of 5 
opportunities.  
Table 19. Intelligibility Across Participants 
Phase Participant 1 Participant 2 Participant 3 Participant 4 Participant 5 
A1 4.67 1.3 14.00 11.33 26.67 
B1 12.67* 0.0 15.67* 31.00* 45.00* 
A2 12.67 0.0 8.33* 17.67* 34.67* 
B2 16.67* 0.0 7.00 16.67 11.45 
Note. *Indicates demonstration of effect; measures are in %. 
Table 20. SBU Across Participants 
Phase Participant 1 Participant 2 Participant 3 Participant 4 Participant 5 
A1 1.0 3.4 3.8 6.0 5.0 
B1 2.9* 4.2* 4.2* 6.3* 6.0* 
A2 1.8* 3.2* 3.5* 6.1* 2.5* 
B2 2.3* 5.0* 4.1* 5.7 6.5* 
Note. *Indicates demonstration of effect.  
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Table 21. Summary of Changes in Rib Cage ROM Across Participants 
Phase Participant 1 Participant 2 Participant 3 Participant 4 Participant 5 
A1 A=. 40 
N= .42 
X= .58 
AB=21.00 
A= .52 
N= .21 
X= .23 
AB=19.00 
A=. 31 
N= .33 
X= .54 
AB=20.00 
A= .17 
N=. 29 
X= .31 
AB= 21.00 
A= .83 
N= .81 
X= .42 
AB=19.06 
B1 A= .98* 
N= .71* 
X=. 94* 
AB=17.50* 
A= .69* 
N= .81* 
X=1.25* 
AB=19.50 
A= .75* 
N= .9* 
X= 1.02* 
AB= 19.00* 
A= .67* 
N= .88* 
X= .75* 
AB= 20.00* 
A= .75 
N=.83* 
X= .52* 
AB= 19.00 
A2 A= .65* 
N= .52* 
X= .65* 
AB=21.50* 
A= .38* 
N= .58* 
X= .54* 
AB=19.00 
A= .42* 
N= .33* 
X= .56* 
AB= 20.00* 
A= .19* 
N= .29* 
X= .33* 
AB= 21.00* 
A= .56* 
N= .47* 
X= .44* 
AB= 19.63* 
B2 A=. 77* 
N= .83* 
X= .85* 
AB=20.00* 
A=1.05* 
N=1.04* 
X=1.19* 
AB=19.00 
A= .94* 
N= .81* 
X= .63* 
AB= 20.00 
A=1.10* 
N=.79* 
X=.94* 
AB=19.00* 
A= .94* 
N= .85* 
X= 1.65* 
AB=19.00* 
Notes. *Indicates demonstration of effect; A = axilla, N = nipple, X = xyphoid, and AB = 
abdominal circumference; All measurements are in inches.   
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CHAPTER 5. 
DISCUSSION 
 
 This Phase II, A-B-A-B single-subject experimental design study was replicated across 
five participants and used demonstrations of effect for primary and secondary outcome measures 
to evaluate the treatment efficacy of a manual therapy protocol on speech outcomes in children 
with spastic cerebral palsy. Given the heterogeneity of children with CP, the use of single-subject 
experimental design was used to support the development of a treatment for this population. 
Treatments addressing respiratory function are profoundly needed to address the foundation of 
the speech disorder. The known literature intended to support SLPs and researchers in making 
evidence-based treatment decisions are perforated with design problems including: little 
consistency in treatment duration, protocols and frequency.  
 Although current research in the area of physical therapy supports the use of manual 
therapy to increase rib cage ROM (e.g. Jerome et al., 2013), no research was located reflecting 
its impact on speech production. Given respiration is the foundation for speech production 
(Massery, 2012) and the rib cage contributes 84% of pressure for that process in children in this 
age range (Hoit, Hixon, et al., 1990; Stathopoulos & Sapienza, 1997), using the strategies 
employed by PTs to increase mobility of the chest wall could likely result in positive changes in 
the intensity and duration of phonation and possibly affect speech intelligibility and SBU. The 
results of the present study reveal a treatment effect in speech intensity (dB SPL) and SBU when 
provided one week on the manual therapy protocol. Treatment effects were not found for 
duration of phonation and speech intelligibility.  What follows is a more in-depth discussion 
about the results according to each experimental question and individual results. Lastly, 
theoretical implications, research implications, clinical implications, and study limitations will be 
addressed.  
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Question 1 
Question 1 aimed to determine the presence of treatment effects of a manual therapy 
protocol on speech outcomes, SPL and MPD in children diagnosed with spastic CP. I 
hypothesized an accelerating trajectory change of SPL and MPD would occur upon initiation of 
the manual therapy protocol.  Upon withdrawal of the treatment, the trajectory of the primary 
outcome measures would return toward baseline measures. These hypotheses were based on the 
current literature in physical therapy and speech therapy that yields results that point to a 
treatment effect influencing lung volume and ROM (Jerome et al., 2013; Jones et al., 2014).  
All five participants demonstrated a large treatment effect (Cohen, 1988) evidenced by 
change in SPL measurements and data analyses including: trend, level, variability, immediacy of 
effect, % of NOD, and effect sizes. MPD results were less consistent. Possible explanations for 
this discrepancy are discussed below. 
Three possibilities for the inconsistent MPD results come to mind. First, the language 
abilities of the participants should be considered as many children with cerebral palsy have 
language deficits (Hustad, Schueler, Schultz, & DuHadway, 2012). Each participant was given 
the CELF Pre-School-2 (Wiig et al., 2004), and their Core Language Scores ranged from 45 to 
88. All participants had below average receptive language abilities ranging from 55-77, which 
may have accounted for only 2 of 5 participants understanding the concept of “long”. 
Furthermore, receptive language deficits may have prevented Participants 1, 2, and 3 from 
understanding and following the 2-part prompt, “Say/a/ as loud and long as you can.”  In future 
studies the ability to follow two-step commands and the receptive knowledge of the concept 
“long” could be added to the inclusion criteria.  
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A second possibility for MPD inconsistencies may have to do with treatment duration. In 
the pilot study, the participant received 6 weeks of manual therapy, which elicited improvements 
in MPD (Varnado et al., 2014). It is possible that changes in MPD require longer treatment 
duration and/or more intensive motor practice to enable the controlled release of air during 
exhalation. Only direct and systematic replication of the present study will resolve the present 
inconsistencies related to MPD.   
In working with children who have lower language abilities, it might be more beneficial 
to change the primary outcome measure from MPD to SBU in spontaneous speech. SBU was a 
secondary outcome measure in this study; however, in 14 of 15 opportunities participants’ 
numbers increased and decreased as predicted provided the administration or withdrawal of 
treatment.  Furthermore, SBU may be a more functional measure of speech output since it can be 
produced at the participant’s usual vocal loudness. Last, a measure of SBU could be useful, not 
only for children who have receptive language deficits, but also for those who are producing pre-
speech vocalizations (e.g. producing jargon or babbling)  
A third explanation, could be that participants need more motor practice to have the 
motor control required to produce longer utterances. This is supported by the variability between 
the first and second treatment phases for Participant 1. He did not demonstrate a change in data 
trajectory during the first treatment phase (B1); however, he did so in the second treatment phase 
(B2). It might be that once he was able to master the intensity portion of the task, he was able to 
use newly available cognitive effort or attention to be “loud and long”.  
Question 2 
The second research question targeted the effects of the treatment protocol on functional 
communication (speech intelligibility and SBU). It should be the ultimate goal of speech therapy 
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for treatment goal achievements to translate to activities and participation in daily life (Donovan, 
Kendall, Young, & Rosenbek, 2008).  
There is little of information available regarding how speech intelligibility and cognitive 
and/or linguistic levels are affected by the development and impairment present in children with 
severe motor impairments. The current study examined intelligibility descriptively to provide 
information regarding the functional communication effects of the treatment protocol and guide 
future studies in the examination of the dosage adequate to elicit functional communication 
changes. Small sample size, variation of the presentation of function in individuals with CP, and 
language level of each participant could have contributed to the large variability in the secondary 
outcomes in the current study. Furthermore, participants with higher cognition and semantic 
abilities would have likely performed better on the sentence repetition task. Those with reduced 
cognitive and language abilities likely experienced a higher cognitive load during the sentence 
repetition task and decreased attention to speech motor control. The sentences used in this study 
included more complex vocabulary and syntactic structures as the stimuli were obtained from an 
intelligibility test normed for ages 12 and older. Morgan, Hodge, and Pennington (2015) confirm 
the lack of availability of a suitable tool to assess intelligibility in connected speech in children.  
The participants in the current study received 2 non-concurrent weeks of treatment did 
not experience a similar change in speech intelligibility as compared to the participant in the 
pilot study who received six weeks of treatment (Varnado et al., 2014). Definitive judgments as 
to why this is the case are not possible due to the comparison of only one participant in the pilot 
study and five participants in the current study.  
Normative data were not located for SBU for children ages 4-6 years old. Hixon and Hoit 
(1987) reported results of healthy men; however, for many reasons this data cannot be applied to 
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children. In 14 of 15 opportunities, changes in SBU provided the implementation or withdrawal 
of treatment indicate functional communication change in these participants. Production of more 
words per breath unit could reduce fatigue during connected speech production. Further research 
including this variable in typical and disordered children may provide knowledge whether this 
indicator can be linked to changes in quality of life measures. 
Finally, Participant 2 in the present study presented both dysarthria and apraxia. Her 
intelligibility measures ranged from 0 to 1.3%. Although measures of intensity and SBU 
indicated change, the apraxia could have contributed to the decrements in intelligibility. Further 
research to address dosage would help identify and explain the differences present.  
Question 3 
Question 3 sought to establish if the manual therapy protocol changed the mobility of the 
rib cage (chest expansion) and reduced abdominal protrusion. The study by Jerome et al (2013) 
found support that such change would occur; however, that study neither described the therapy 
procedures nor the speech outcomes. It was hypothesized that the difference in rib cage 
circumference at each location would increase after treatment was initiated and decrease upon 
treatment withdrawal. Furthermore, abdominal protrusion would decrease after treatment was 
initiated and increase upon treatment withdrawal. 
In 44 of 45 opportunities, the ROM increased/decreased as treatment was provided or 
withdrawn as expected. These results provide further support that reduction in spasticity would 
allow for increased breath support for speech also strengthening the support for a positive 
treatment effect. This supports the Jerome et al. (2013) that demonstrated manual therapy 
including stretch increases rib cage ROM in children with spastic cerebral palsy. That study also 
found abdominal protrusion decrease upon implementation of treatment. In the present study the 
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circumference of the abdomen increased/decreased as treatment was provided or withdrawn in 7 
of 15 opportunities. These results were not as consistent as those in the Jerome et al. (2013) 
study. It should be noted that the measurements of the abdomen changed as hypothesized for 
those participants who had more severe motor involvement. Participants 1 and 4 are wheelchair 
dependent and have minimal opportunity to practice the oppositional motor movements required 
to promote rib cage development and maintain structural changes attained in the present study. 
Participants 2, 3, and 5 do have movement restrictions; however, they are able to move more 
freely. Their rib cage development prior to the initiation of the study exceeded that of 
Participants 1 and 4.  
In summary, the results of this study indicate a treatment effect is present affecting SPL, 
SBU, and rib cage ROM.  No treatment effect was elicited affecting MPD and intelligibility. 
These results may contribute to a better theoretical understanding of the application of motor 
learning principles and exploiting neuroplasticity in children with spastic cerebral palsy. 
Theoretical Implications 
Currently, two broad areas of research that could be influenced by these results include 
the use of motor learning principles in speech therapy and capitalizing on neuroplasticity in 
speech therapy. Current treatment research in motor speech seeks to determine if implementation 
of motor learning principles will elicit functional change in speech outcomes (Maas & Farinella, 
2012; Maas et al., 2008). Stimuli selection, practice structure, and feedback conditions has 
proven to increase performance and learning (e.g. Wambaugh, Nessler, Cameron, & Mauszycki, 
2012, 2013; Wambaugh, Nessler, Wright, & Mauszycki, 2014). A component of these principles 
not addressed currently in the literature is the reduction, alteration or elimination of individual 
structural constraints. It is the ultimate goal of this research to determine if reducing the 
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movement constraints impeding the ROM of will promote functional changes resulting in 
increased breath support for speech production or possibly enable motor practice to occur. 
Another recurring theme in the treatment of neuromotor disorders is neuroplasticity. 
Although neuroimaging has provided large amounts of information about injury and recovery, 
little has linked the brain lesions to speech outcomes in children. Anderson (2011) reported the 
highest phase of plasticity occurs in children ages 3 to 6 years old, describing the period of time 
pre-and post- as having reduced plasticity. This evidence closely parallels the “critical period” of 
language development discussed by Lennegerg’s Critical Period Hypothesis (1967) of language. 
Emphasis on this important time in development should be accounted for in further research 
addressing motor speech disorders, neuroplasticity and children. Combining Anderson’s 
contribution to Lennegerg’s points to likely the most valuable time for treatment in children with 
motor speech impairments. This time period should be utilized optimally to elicit maximum 
therapeutic outcomes. 
Lastly, a high frequency of motor practice is required to elicit cortical changes (L. J. Carr 
et al., 1993; D. R. Lee et al., 2014). A change in individual structural constraints may be required 
to enable this practice, especially at the dosage required for change. The present study is a step 
toward discriminating the rolls of motor learning and neuroplasticity given this manual therapy 
protocol. The results of this study support the need for further research to address these treatment 
questions. 
Research Implications/Future Research 
There is abundant literature regarding the importance of respiratory function in the 
production of audible and intelligible speech (Hixon, 1973; Massery, 2012); however, minimal 
research exists addressing the treatment of respiratory function to affect speech outcomes in 
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children with severe motor impairments (Butler & Darrah, 2001; Knox & Evans, 2002). Current 
literature does not provide sufficient evidence to enable firm treatment recommendations 
resulting in the use of treatments that are not evidence-based or ideal for the patients. Variability 
in the population of children with CP prevent the application of large-scale randomized control 
trials; therefore, the use of systematic and direct replication of single-subject design studies 
would most contribute to the development of evidenced-based treatments (Levy, 2014). 
Modifications to the methods could provide more specific information as to the effect of 
manual therapy treatment.  Collecting sound pressure level of spontaneous speech or speech 
samples of preselected sentence list as the primary outcome measure in place of the MPD of /a/ 
would give knowledge of performance changes more directly reflecting communicative 
competence. Additionally, obtaining measures both before and after the treatment would help 
separate the transient versus residual effects of the treatment.  
The complex symptomology of children with CP complicates studies such as this one. 
The participants in this study were identified with respiratory complications that affected speech 
outcomes. Two participants had personal nurses that followed them throughout their day to 
ensure adequate care. One of these participants was eventually excluded from the study due to 
extended gaps in treatment time or phase shifts due to respiratory complications that required 
steroid medications, hospitalizations, and other medications to improve respiratory function. 
Additionally, respiratory illness is common in the months of January and February (e.g. Dawson-
Caswell & Muncie, 2011; Epperson et al., 2014). Some participants did participate when minor 
respiratory illness arose and continued to attend school. In the case of Participant 2, the other 
participant with a personal nurse, there is a large decelerating shift in the SPL data trajectory 
when she started to have a runny nose. Lastly, Participant 5 exhibited the same pattern when she 
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became congested in the first treatment phase (B1). Future researchers cannot avoid these 
happenings; however, awareness may guide research design choices such as conducting the 
study in the summer and fall when respiratory illness is less active. 
 Extensions of this study should include groups of specific age groups (1-2 years, 3-5 
years, 6-9 years, 10-15 years, and 16- adulthood). These increments were chosen based on motor 
and language developmental changes that separate the distinct groups. For participants in the 
youngest group or those with decreased or questionable levels of cognition, primary outcome 
variables could be modified to include the SPL of spontaneous communication attempts and 
number of SBU during jargon or babbling. Furthermore, other diagnoses that include spasticity 
should be explored including stroke, traumatic brain injury, multiple sclerosis and stroke.  
 Optimal dosage should be explored. Questions including at what dosage do participants 
plateau, what dosage is required to achieve maintenance, and what dosage is required before 
transitioning to a home program are each areas to be addressed. Given the current culture of 
minimal coverage for therapy by insurance companies, efficacy and efficiency are paramount. 
Answering the dosage questions will enable implementation of the most valuable treatments to 
achieve optimal results. 
 Although SPL and MPD are valuable measures to assess changes in voice and respiratory 
function, inclusion of s/z ratio (Eckel & Boone, 1981) in the primary outcome measures or initial 
screening procedures would help discriminate the cause of the functional presentations of short 
utterances, breathy voice, reduced volume, and poor intelligibility. Using this measure as a 
screening for inclusion criteria would help to ensure that the treatment is optimal for the patient. 
Use of s/z ratio as a primary outcome measure could provide information as to how the treatment 
protocol affects both respiratory function and voice.  
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Consideration for home programs either completed by the patient or augmented by the 
caregiver could also be of value. Training caregivers or patients complete this or a modified 
version of the protocol in the home environment may increase maintenance of the changes 
achieved during treatment. Furthermore, therapy time could be utilized to make progress in other 
areas such as language development if the rib cage ROM can be maintained by implementation 
of the protocol at home. 
The ultimate goal of therapy is to maximize communicative effectiveness. Future studies 
might seek to determine if the motor speech improvements derived from the treatment presented 
in this study contribute to production of longer, more complex utterances. If increased SBU leads 
to increased mean length of utterance then there would be evidence to support what is a 
commonly held belief at this time that enhanced respiratory function enables a child to produce 
more language. This study did not measure any aspects of communication beyond speech 
intelligibility.  However in order to determine whether the treatment had any effect on a child’s 
communicative effectiveness beyond the treatment setting, a more detailed measure of functional 
communication could be used. Poor speech intelligibility limits communicative interactions, 
participation in life situations, and perceived quality of life (Pennington et al., 2013). A measure 
of this sort could examine the carryover of motor speech changes elicited in therapy and/or 
identify optimal communication environments and communication partners to maximize 
communicative effectiveness.  
The results of this study provide evidence for a line of research that evaluates practices of 
other disciplines and their possible impact on speech outcomes. OTs and PTs, especially, have 
valuable information that SLPs should consider incorporating in to treatment protocols and 
research agendas. 
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Clinical Implications 
Language impairments are often present in children with CP and should be targeted in 
speech-language therapy services. The sound pressure level results of MPD of /a/ likely 
measures the transient effects of stretch, not permanent changes in the muscle capability. 
Therapists may be able to use this temporary improvement prior to language therapy to enable 
more complex expressive language practice and skill learning in the treatment setting. Treatment 
including increased dosage and more active practice could results in more permanent motor and 
ROM changes allowing for continued language practice after treatment sessions. Only extension 
of the present study can confirm or refute this hypothesis. 
A benefit of this protocol enables the stretches to be augmented by therapists in patients 
with decreased cognition or if cognition is uncertain due to poor communication abilities. Other 
treatment options require the ability to follow directions and an understanding of concepts that 
may exceed the patient’s cognitive abilities. The behaviors used to measure progress can be 
modified based on the cognition and motor control of the patient. 
In addition to addressing the limitations in current research, this study’s procedures give 
information regarding the feasibility of implementing this treatment in typical treatment settings. 
All of the participants were seen at school outside of instructional time as to not interfere with 
any ongoing treatments. The short duration of the treatment allowed ease of scheduling into the 
participants present schedules. 
While this study has established the treatment efficacy for a manual therapy treatment, 
direct and systematic replication is needed before determining treatment effectiveness (phase 3) 
(Kratochwill et al., 2010). However, because SLPs have clients in need of manual therapy at this 
time, the raw data for all participants are included in Appendices J to N to assist clinicians in 
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deciding if they have patients who may benefit from this protocol. SLPs interested in 
implementing this protocol should collaborate with a PT to ensure proper technique. If patients 
require additional therapy goals, manual therapy treatment could be completed prior to 
articulation and language therapies that may be the focus of a given session.  
I encourage SLPs to utilize s/z ratio to assist in identifying whether respiratory or 
phonatory impairments (or a combination of the two) are contributing to the motor speech 
disorder. Perceptually, respiratory impairments and phonatory impairments may sound similar 
during speech tasks; therefore, it is important to determine the status of each subsystem prior to 
initiation of this manual treatment protocol. Furthermore, some SLPs may be uncomfortable 
implementing this type of therapy due to lack of experience. I encourage those therapists to 
consult with the patient’s PT. The PTs could be educated on the role of the in speech production 
and the benefits of increased ROM of the rib cage for the production of speech. PT could 
possibly support speech therapy efforts by providing manual therapy or other treatments to 
reduce spasticity of the resulting in increased level of functioning for the patient.  
Contributions of each healthcare discipline add to the overall success of any treatment 
plan. It is vital that SLPs understand the impact that other disciplines’ treatments may have on 
speech-language outcomes. Likewise, it is important for other disciplines to understand how their 
treatments affect speech-language outcomes. In addition to rib cage ROM, trunk support, and 
positioning are other areas that the PT could support the SLP in increasing respiratory function 
for increased speech outcomes for complex cases. Referral to or collaboration with PT could 
greatly impact our speech outcomes. 
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Limitations 
Several limitations should be considered. The sound pressure level measures of MPD of 
/a/ likely measures the transient effects of stretch, not permanent changes in the muscle 
capability. Although this is discussed as a limitation, practitioners should use this to their 
advantage when devising treatment plans by implementing manual therapy prior to and in 
conjunction with motor practice to achieve therapy goals. Katalinic et al. (2011) discusses in a 
systematic review of the literature the effectiveness is likely dependent on dosage and how the 
stretch is applied. While dosage is explicitly defined in the majority of the literature, type and 
procedures of stretch are not. More specificity is needed across disciplines.  
The measurements of SPL and MPD of /a/ was used in previous studies because they are 
a standard in the diagnosis in voice disorders. Some participants were able to produce short 
bursts of phonation with higher sound pressure levels. The same participant would likely not 
have been able to reach the higher sound pressure level if they had sustained phonation. It is 
unclear if the participants’ understanding of the prompt “Say /a/ as loud and as long as you can.” 
elicited phonation attempts that included longer durations. The “louder” part of the prompt 
appeared to be comprehended and followed; however, the “longer” part was less evident in 
changes in performance. This should not be of concern with older participants or participants 
with higher cognition; however, in the case of the younger participants this prompt should be 
examined.  
It should be noted randomized lists of 5-word sentences from Intelligibility of Dysarthric 
Speech (Yorkston & Beukelman, 1981) were used to collect the speech samples from which 
SBU counts were extracted. Although, participants were rarely able to correctly imitate the 
complete sentence the amount of cognitive load may have contributed to or interfered with motor 
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speech performance. The syllables present in the prompts per phase ranged from 64 to 76 
syllables. The individual sentences ranged from 5 to 9 syllables. These differences should be 
considered when interpreting the present results and in design of future studies.  
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CHAPTER 6. 
CONCLUSION 
 
In conclusion, the results presented provide evidence to support a large treatment effect 
for a manual therapy protocol on speech outcomes including SPL, SBU, and chest expansion. 
The current evidence was less consistent for MPD and intelligibility measures. Only direct and 
systematic replication utilizing single subject design will enable results to be confirmed and 
generalized. This study is the first to discuss using manual therapy treatments that are proven to 
increase rib cage ROM to elicit speech outcomes. Using motor learning principles has proved 
successful in treating motor speech disorders; however, addressing individual structural 
constraints has not. This study is the first to apply that component to treating motor speech 
disorders in children.  
If the results of this study are replicated, the course of treatment for children with 
neurological impairments may be altered. By addressing constraints prior to motor or language 
practice, treatment outcomes could be improved. Although this treatment does not require active 
participation, the motor practice required for motor learning and/or cortical change does. It is 
unclear at this time what role that may play in the implementation decisions related to this 
protocol. 
According to the parameters defined by Kratochwill (2010), this study “meets evidence 
standards” (p.14) for design quality and presents “strong evidence” (p. 21) of treatment efficacy. 
The criteria indicate the present study adds a strong piece of evidence to the literature, addressing 
rib cage ROM to increase speech outcomes in children with spastic CP.  Furthermore, these 
results hold promise for other disorders with a spastic component. Additionally, it introduces the 
application of treatment from other therapy disciplines to address speech therapy outcomes in 
individuals with motor speech disorders.  
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Risk Factor: Minimal                    Uncertain        X          Greater Than Minimal_______              
 
Approved       X           Disapproved ___________ 
 
Approval Date: 10/16/2014   Approval Expiration Date: 10/15/2015 
 
Re-review frequency: (annual unless otherwise stated) 
 
Number of subjects approved:   11 
 
LSU Proposal Number (if applicable):     
 
Protocol Matches Scope of Work in Grant proposal: (if applicable)     
 
By: Dennis Landin, Chairman       
 
PRINCIPAL INVESTIGATOR: PLEASE READ THE FOLLOWING –  
Continuing approval is CONDITIONAL on: 
1. Adherence to the approved protocol, familiarity with, and adherence to the ethical standards of the Belmont Report, 
and LSU's Assurance of Compliance with DHHS regulations for the protection of human subjects* 
2. Prior approval of a change in protocol, including revision of the consent documents or an increase in the number of 
subjects over that approved. 
3. Obtaining renewed approval (or submittal of a termination report), prior to the approval expiration date, upon   request 
by the IRB office (irrespective of when the project actually begins); notification of project termination.  
4. Retention of documentation of informed consent and study records for at least 3 years after the study ends. 
5. Continuing attention to the physical and psychological well-being and informed consent of the individual participants 
including notification of new information that might affect consent. 
6. A prompt report to the IRB of any adverse event affecting a participant potentially arising from the study.  
7. Notification of the IRB of a serious compliance failure. 
*All investigators and support staff have access to copies of the Belmont Report, LSU's Assurance with DHHS, DHHS (45 
CFR 46) and FDA regulations governing use of human subjects, and other relevant documents in print in this office or on 
our World Wide Web site at http://www.lsu.edu/irb  
Institutional Review Board 
Dr. Dennis Landin, Chair 
130 David Boyd Hall 
Baton Rouge, LA 70803 
P: 225.578.8692  
F: 225.578.5983 
irb@lsu.edu | lsu.edu/irb 
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APPENDIX C. INFORMED CONSENT 
 
Consent Form 
 
Project Title:  Treatment effect of a manual therapy protocol on speech outcomes for children 
with spastic cerebral palsy: A single subject experimental design 
Performance Site:   
Investigators:  The following investigators are available for questions, Monday-Friday 8:00 
a.m.-4:30 p.m. 
Chantelle B. Varnado, M.S. CCC-SLP  Neila Donovan, Ph.D., CCC-SLP 
Department of Communication Disorders, LSU Department of Communication Disorders, LSU 
(225) 405-8627     (225)578-3938 
 
Purpose of the Study:  To know if stretching rib muscles helps make speech louder. 
Inclusion Criteria:  good hearing and vision, able to follow simple directions, and has a motor 
delay 
Exclusion Criteria:  active seizure activity, uncontrolled asthma, upcoming surgeries, 
significant scoliosis affect breathing 
Description of the Study:  The study will last four weeks, 2 weeks of treatment and two weeks 
with no treatment. We will stretch your child’s rib muscles for 15 minutes daily during the weeks 
of treatment. This will be added to your child’s therapy plan. Your child will get all of his/her 
other therapies as usual.  After stretching, we will measure how loud and how long your child 
can make the “ah” sound. We will also measure during the weeks your child does not receive 
treatment. 
Benefits:  You will not be paid for this study. You and your child are helping us learn more 
about stretching and speech. 
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Risks:  Many children receive these stretches. They do not put your child’s health at risk. We 
will watch your child carefully for any problems. 
Right to Refuse:  This is a volunteer study. You do not have to be in it. If you decide that you do 
not want your child in the study, you can say no or stop the study at any time. Even if you decide 
not to be in the study, it will not change your child’s care. 
Privacy:  We will protect your child’s privacy. We replace names with secret codes. Only my 
research helpers and I know the code. We will keep everything double-locked. We also use a 
special password to get in our computer. We never use any information that could identify your 
child if we write about this study. 
Financial Information:  There is no cost for participation in this study, and you will not be paid 
for participation in this study. 
Thank you for your participation! 
If you have any questions about the study, you can ask the investigators at any time. 
Signatures: 
The researcher discussed the study with me.  She answered all of my questions.  I 
understand that if I have any other questions, I can call the researchers, Chantelle Varnado or Dr. 
Neila Donovan.  I understand that if I have any questions about my rights or any other concern 
about the research, I can contact Denis Landin, Institutional Review Board, at (225)578-8692. 
I agree to let my child to be in the study described above. I understand that the researcher must 
give a signed copy of this consent form. 
________________________________   _______________________ 
Signature of Parent      Date 
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APPENDIX D. PHOTO CONSENT FORM 
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APPENDIX E. GROSS MOTOR FUNCTION LEVEL 
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(Palisano et al., 2012) 
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APPENDIX F. COMMUNICATION FUNCTION CLASSIFICATION SYSTEM 
 
 
(Hidecker et al., 2011) 
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APPENDIX G. TREATMENT FIDELITY CHECKLIST 
Participant #:____________     Date:_________________ 
Task Comply Failed to 
Comply 
Tasks counter-balanced   
Anterior Intercostal Stretch 
Participant sit facing away from the therapist   
Therapist seated behind participant   
Use pads of fingers   
Begin at sternum moving laterally   
Repeated in each rib space   
Posterior Intercostal Stretch 
 
Participant sit facing the therapist   
Therapist seated in front of participant   
Use pads of fingers   
Begin at vertebrae moving laterally   
Repeated in each rib space   
Lateral Intercostal Stretch 
Participant sit facing away from the therapist   
Therapist “L”-shape hands   
Begin at highest rib space   
Work on lateral chest wall   
Participant’s opposite arm over head   
Therapist cue “Reach”   
Therapy ball roll to opposite direction   
Completed bilaterally   
Bolster Stretch 
Participant side-lying on bolster   
Therapist “L”-shaped hands   
Begin at highest rib space   
Work on lateral chest wall   
Participant’s opposite arm over head   
Therapist cue “Reach”   
Repeated in each rib space   
Intercostal Percussion 
Participant sit facing away from the therapist   
Therapist “L”-shaped hands   
Begin at highest rib space   
Prompt “Take a deep breath in, and push all the air 
out.” 
  
Therapist shake and pull down on  until exhalation is 
complete 
  
Repeated in each rib space   
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APPENDIX H. MEASUREMENT FIDELITY CHECKLIST 
 
Procedure                  Participant                       Session # Yes No 
SLM 6 inches from mouth   
Microphone positioned in front of mouth   
Prompt “Say /a/ as loud and long as you can.”   
Child seated upright and supported   
Reset button is pressed immediately after prompt   
 
Procedure                  Participant                       Session # Yes No 
SLM 6 inches from mouth   
Microphone positioned in front of mouth   
Prompt “Say /a/ as loud and long as you can.”   
Child seated upright and supported   
Reset button is pressed immediately after prompt   
 
Procedure                  Participant                       Session # Yes No 
SLM 6 inches from mouth   
Microphone positioned in front of mouth   
Prompt “Say /a/ as loud and long as you can.”   
Child seated upright and supported   
Reset button is pressed immediately after prompt   
 
Procedure                  Participant                       Session # Yes No 
SLM 6 inches from mouth   
Microphone positioned in front of mouth   
Prompt “Say /a/ as loud and long as you can.”   
Child seated upright and supported   
Reset button is pressed immediately after prompt   
 
Procedure                  Participant                       Session # Yes No 
SLM 6 inches from mouth   
Microphone positioned in front of mouth   
Prompt “Say /a/ as loud and long as you can.”   
Child seated upright and supported   
Reset button is pressed immediately after prompt   
 
Procedure                  Participant                       Session # Yes No 
SLM 6 inches from mouth   
Microphone positioned in front of mouth   
Prompt “Say /a/ as loud and long as you can.”   
Child seated upright and supported   
Reset button is pressed immediately after prompt   
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APPENDIX I. RANDOMIZATION OF TREATMENT TASKS 
 
Participant 1 
Week 2: 4, 3, 5, 2, 1 
Week 3: 2, 3, 4, 1, 5 
Week 4: 1, 3, 2, 4, 5 
 
Participant 2 
Week 2: 1, 5, 2, 4, 3 
Week 3: 4, 2, 3, 1, 5 
Week 4: 3, 2, 1, 5, 4 
 
Participant 3 
Week 2: 3, 4, 2, 1, 5 
Week 3: 3, 4, 5, 1 2 
Week 4: 5, 2, 3, 4, 1 
 
Participant 4 
Week 2: 3, 5, 2, 4, 1 
Week 3: 3, 2, 1,4, 5 
Week 4: 1, 2, 4, 5, 3 
 
Participant 5 
Week 2: 4, 2, 3, 5, 1 
Week 3: 1, 3, 4, 5, 2 
Week 4: 2, 4, 5, 1, 3 
 
 
 
 
 
 
 
 
 
 
 
  
92 
APPENDIX J. PARTICIPANT #1 RAW DATA 
DATA COLLECTION 
Participant #:       1          Age:      4        Diagnosis:   Spastic Cerebral Palsy 
Gender:    M        GMFS:   V            CFCS       III           
Receptive:        75          Expressive:      63             Core:     75  
  
Week 1(A1) 
Sequence      
SPL 73.1 82.9 85.1 81.5 84.9 81.8 83.1 74.1 72.3 75.3 74.4 76.4 83.4 82.1 75.3 
AVG SPL 80.57 82.73 76.50 75.37 80.27 
AVG Dur. .34 .39 .34 .17 .28 
AVG Intell. SBU Nipple Axilla Xyphoid Abdomen 
4.67 % 1.0 .50 in. .25in. .75 in. 21.0 in. 
  .25 in. .63 in. .50 in.  
  .50 in. .31 in. .50 in.  
Week 2(B1) 
Sequence 4 3 5 2 1 
SPL 81.3 83.3 82.6 87.3 88.6 86.2 94.2 85.8 93.3 90.1 87 84.3 94 84.6 85.2 
AVG SPL 82.3 87.31 91.1 87.13 87.93 
AVG Dur. .31 .2 .27 .2 .22 
AVG Intell. SBU Nipple Axilla Xyphoid Abdomen 
12.67 % 2.9 .69 in. 1.00 in. 1.25 in. 17.5 in. 
  .63 in. 1.06 in. .75in.  
  .81 in. .88 in. .81 in.  
Week 3 (A2) 
Sequence 2 3 4 1 5 
SPL 77.7 80.5 81.5 82 84.4 82.3 74.4 83.4 74.6 71.1 83.3 81.4 75.2 83.8 76 
AVG SPL  79.9 82.9 77.47 78.8 78.33 
AVG Dur. .25 .3 .32 .22 .25 
AVG Intell. SBU Nipple Axilla Xyphoid Abdomen 
12.67 % 1.8 .50 in. .75 in. .31 in. 21.5 in. 
  .44 in. .75 in. .56 in.  
  .63 in. .69 in. .38 in.  
Week 4 (B2) 
Sequence 1 3 2 4 5 
SPL 85.6 84.4 78.4 87.6 91.3 88.2 87.4 90.6 93.2 90.3 89.5 89.2 88.3 93.4 94.9 
AVG SPL 82.8 89.03 90.41 89.67 92.2 
AVG Dur. .28 1.98 2.61 1.83 2.69 
AVG Intell. SBU Nipple Axilla Xyphoid Abdomen 
16.67 % 2.3 .63 in. .69 in. .75 in. 20.0 in. 
  1.00 in. 1.13 in. .88 in.  
  .88 in. .56 in. .56 in.  
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APPENDIX K. PARTICIPANT #2 RAW DATA 
DATA COLLECTION 
Participant #:    2     Age:    4        Diagnosis:    Spastic CP/Apraxia 
Gender:     F             GMFS:       IV         CFCS       V           
Receptive:        55             Expressive:      53                Core:    55       
 
Week 1(A1) 
Sequence      
SPL 87.9 81.3 83.4 79.2 83.4 81.7 81.3 79.2 80.5 85.6 81.2 80.8 89.8 71.2 73.2 
Avg SPL 84.2 81.43 80.33 82.57 78.01 
Avg Dur. 1.45 1.82 1.24 2.25 .8 
 Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
1.30% 3.4 .25 in. .63 in. .25in. 19.0 in. 
  .25 in. .50 in. .25 in.  
  .13 in. .44 in. .19 in.  
Week 2(B1) 
Sequence 1 5 2 4 3 
SPL 90.7 85.1 87.7 91.8 82.1 97 97.3 90.4 93.2 88.8 96.3 91.2 86.5 92.5 92.3 
Avg SPL 87.83 90.3 93.63 92.1 90.43 
Avg Dur. 1.15 1.22 1.67 1 .97 
Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
0.00% 4.2 .69 in. .56 in. 1.25 in.  19.5 in. 
  .88 in. .75 in. .75 in.  
  1.25 in. .75 in. 1.75 in.  
Week 3 (A2) 
Sequence 4 2 3 1 5 
SPL 83.3 84.7 87.2 68.6 79.3 78.2 87.6 82.4 91.2 78.7 76.7 75.7 70.3 76.7 71.3 
Avg  SPL  85.07 75.37 87.07 77.03 72.77 
Avg Dur. .72 1.06 .93 .95 1.24 
Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
0.00% 3.2 .75 in. .44 in. .44 in. 19.0 in. 
  .50 in. .38 in. .63 in.  
  .50 in. .31 in. .50 in.  
Week 4 (B2) 
Sequence 3 2 1 5 4 
SPL 88.6 89.7 86.3 83.8 88.7 80.6 78.5 85.1 80.1 92.3 93.7 95.9 101.3 102.1 99.2 
Avg  SPL 88.2 84.37 81.23 93.97 100.87 
Avg  Dur. 1.57 1.44 1.44 .97 1.39 
Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
0.00% 5 1.00 in. .75in. 1.25 in. 19.0 in. 
  1.25 in. 1.13 in. 1.25 in.  
  .88 in. 1.19 in. 1.06 in.  
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APPENDIX L. PARTICIPANT #3 RAW DATA 
DATA COLLECTION 
Participant #:  3      Age:     4         Diagnosis:    Spastic CP 
Gender:        F           GMFS:_      II          CFCS    III_ 
Receptive:    75             Expressive:     81             Core:      81       
Week 1(A1) 
 
Week 2(B1) 
Sequence 3 4 2 1 5 
SPL 90.3 88.2 89.5 93.1 89.7 92.1 91.1 91.7 94.3 91.4 89.8 88.9 94.2 90.7 90.9 
Avg SPL 89.33 91.63 92.37 90.03 91.93 
Avg Dur. .81 1.54 .93 1.24 1.03 
Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
15.67% 4.2 ,81 in. .56 in. .94 in. 19.0 in. 
  .88 in. .75 in. 1.00 in.  
  1.00 in. .94 in. 1.13 in.  
Week 3 (A2) 
Sequence 3 4 5 1 2 
SPL 73.7 87.2 81.3 88.6 82.5 83.9 85.2 85.7 86.6 82.4 83.7 85.9 87.3 81.9 85.7 
Avg SPL  80.73 85 85.83 84 84.97 
Avg Dur. .79 .64 .67 .88 .73 
Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
8.33% 3.5 .25i n. .31 in. .56 in. 20. 0 in. 
  .38 in. .44 in. .50 in.  
  .38 in. .50 in. .63 in.  
Week 4 (B2) 
Sequence 5 2 3 4 1 
SPL 95.7 91.7 93.9 102.1 97.9 101.3 93.5 100 98.2 101.3 99.9 97.6 100.4 96.6 98.8 
Avg SPL 93.77 100.4 97.23 99.6 98.6 
Avg Dur. .65 .92 .99 .59 1.01 
Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
7.00 % 4.1 .56 in. 1.06 in. .50 in. 20.0 in. 
  1.00 in. .81 in. .56 in.  
  .88 in. .94 in. .81 in.  
 
 
 
Sequence      
SPL 80.3 86.2 83.1 87.7 81.2 86.9 85.3 82.5 86.1 85.3 86.2 83.1 84.7 86.3 88.2 
Avg SPL 83.2 85.27 84.63 84.87 86.4 
Avg Dur. 1.51 1.23 1.26 .81 .92 
Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
14.00% 3.8 .38 in. .25 in. .50 in. 20.0 in. 
  .38 in. .19 in. .63 in.  
  .25 in. .50 in. .50 in.  
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APPENDIX M. PARTICIPANT #4 RAW DATA 
DATA COLLECTION 
Participant #:   4      Age:_  5      _ Diagnosis: Spastic CP 
Gender:     F                GMFS:      V          CFCS_     II       
Receptive:   55               Expressive:           59     Core:       53 
  
Week 1(A1) 
Sequence      
SPL 75.1 74.6 73.2 76.1 74.2 71.9 70.1 77.2 83.7 83.2 86.1 81.8 83.2 84.7 81.9 
Avg SPL 74.3 74.07 73.43 83.7 83.27 
Avg Dur. .9 1.22 2.01 2.27 1.60 
Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
11.33% 6 .47 in. .13 in. .31 in. 21.0 in. 
  .25in. .13 in. .25 in.  
  .19 in. .25 in. .38 in.  
Week 2(B1) 
Sequence 3 5 2 4 1 
SPL 89.2 87.3 89.7 84.2 87.3 89.7 89.9 89.3 89.4 87.2 88.8 83.9 86.9 83.7 82.7 
Avg SPL 87.6 87.01 89.53 86.63 85.93 
Avg Dur. 1.28 2.09 2.59 .8 1.30 
Intell. SBU Nipple Axilla Xyphoid Abdomen 
31.00 % 6.3 1.06 in. .81 in. .44 in. 20.0 in. 
  .88 in. .50 in. .63 in.  
  .63 in. .69 in. 1.19 in  
Week 3 (A2) 
Sequence 3 2 1 4 5 
SPL 77.7 77.8 78.8 71.3 73.5 78 81.7 83.8 84 75.3 81.9 80.3 78.9 79.3 81.7 
Avg SPL  78.1 76.27 83.12 79.17 79.9 
Avg Dur. 1.21 2.01 2.4  1.53 
 Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
17.67% 6.1 .1875 .125 .375 21.5 
  .25 .25 .3125  
  .25 .3125 .25  
Week 4 (B2) 
Sequence 1 2 4 5 3 
SPL 84.9 86.2 89.1 85.5 85.6 87.9 93.7 91.7 88.3 90.3 94.8 97.3 85.1 90.8 93.2 
Avg SPL 86.73 86.33 91.23 94.13 89.7 
Avg Dur. 1.29 .94 1.13 .86 1.51 
Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
16.67 5.7 1.00 in. 1,50 in. .94 in. 19.0 in. 
  .81 in. .63 in. 1.07 in.  
  .56 in. 1.88 in. .94 in.  
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APPENDIX N. PARTICIPANT #5 RAW DATA 
DATA COLLECTION 
Participant #:   5 Age:     6        Diagnosis:  Spastic CP 
Gender:         F          GMFS:     II             CFCS:       II         _ 
Receptive:     77             Expressive:       83                    Core:     88          
Week 1(A1) 
Sequence      
SPL 80.3 75.3 82.1 96.5 94.8 92.8 87.3 83.2 90.1 95.9 95.5 94.7 93.7 88.1 87.3 
Avg SPL 79.23 94.7 86.7 95.37 89.7 
Avg Dur. 1.24 1.47 4.89 5.05 3.06 
Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
26.67% 5 .81 in. 1.00 in. .38 in. 19.0 in. 
  .69 in. .94 in. .50 in.  
  .94 in. .57 in. .38 in.  
Week 2(B1) 
Sequence 4 2 3 5 1 
SPL 96
.74 
95.3 97.2 98.2 97.1 100.1 100.
1 
100.
2 
101.
1 
97.7 94.7 96.3 96.9 99.1 97.7 
Avg SPL 79.23 94.7 86.7 95.37 89.7 
Avg Dur. 10.20 13.1 1.64 2.13 1.53 
Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
45.00% 6 .81 in. .75 in. .56 in. 19.0 in. 
  1.0 0 in. .88 in. .44 in.  
  .69 in. .63 in. .56 in.  
Week 3 (A2) 
Sequence 1 3 4 5 2 
SPL 91.3 93.2 96.1 96.7 96.0 99.0 84.3 101.6 96.2 98.1 93.4 91.3 94.1 93.2 91.7 
Avg SPL  93.53 97.23 94.03 94.27 93 
Avg Dur. 2.21 2.95 2.69 3.58 6.53 
Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
34.67% 2.5 .63 in. .38 in. .56 in. 19.6 in. 
  .56 in. .75 in. .31 in.  
  .63 in. .56 in. .44 in.  
Week 4 (B2) 
Sequence 2 4 5 1 5 
SPL 109.1 104.7 104.3 110.1 107.3 97.7 98.8 100.8 98.8 99.7 101.1 98.9 97.9 100.9 101.7 
Avg SPL 106.03 104.9 99.47 99.9 100.17 
Avg Dur. 10.32 10.33 10.21 8.42 6.5 
Avg Intell. SBU Nipple Axilla Xyphoid Abdomen 
11.33% 6.5 .88 in. .6875 2.00 in. 19.0 in. 
  .75 .94 in. 1.38 in.  
  .9375 1.19 in. 1.56 in.  
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APPENDIX O. SPRINGER COPYWRITE PERMISSION LETTER 
 
March 13, 2015 Springer reference 
2005  Cerebral Palsy  ©Springer Science+Business Media, Inc. Freeman	  Miller	  
MD	  DOI	  10.1007/b138647	  Print	  ISBN	  978-­‐0-­‐387-­‐20437-­‐6	  Online	  ISBN	  978-­‐0-­‐
387-­‐27124-­‐8 
Material to be used:	  Figure	  4.5	  (p.106)	  Your project 
PERMISSION LETTER 
01_02 
  
Requestor: 
University: Purpose: 
Chantelle	  B.	  Varnado	  chantelle.varnado@gmail.com	  Louisiana	  State	  
University	  Dissertation/Thesis 
With	  reference	  to	  your	  request	  to	  reuse	  material	  in	  which	  Springer 
Science+Business Media controls	  the	  copyright,	  our	  permission	  is	  granted	  
free	  of	  charge	  under	  the	  following	  conditions: 
Springer material 
  • €represents	  original	  material	  which	  does	  not	  carry	  references	  to	  
other	  sources	  (if	  material	  in	  question	  refers	  with	  a	  credit	  to	  another	  
source,	  authorization	  from	  that	  source	  is	  required	  as	  well);	   
  • €requires	  full	  credit	  (Springer	  and	  the	  original	  publisher,	  
book/journal	  title,	  chapter/article	  title,	  volume,	  year	  of	  publication,	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page,	  name(s)	  of	  author(s),	  original	  copyright	  notice)	  to	  the	  
publication	  in	  which	  the	  material	  was	  originally	  published	  by	  adding:	  
"With	  kind	  permission	  of	  Springer	  Science+Business	  Media";	   
  • €figures,	  illustrations,	  and	  tables	  may	  be	  altered	  minimally	  to	  serve	  
your	  work.	  Any	  other	  abbreviations,	  additions,	  deletions	  and/or	  any	  
other	  alterations	  shall	  be	  made	  only	  with	  prior	  written	  authorization	  
of	  the	  author	  and/or	  Springer	  Science+Business	  Media;	   
  • €Springer	  does	  not	  supply	  original	  artwork	  or	  content.	    This 
permission  
  • €is	  non-­‐exclusive;	   
  • €is	  valid	  for	  one-­‐time	  use	  only	  for	  the	  purpose	  of	  defending	  your	  
thesis	  limited	  to	  university-­‐use	  only	    and	  with	  a	  maximum	  of	  100	  extra	  
copies	  in	  paper.	  If	  the	  thesis	  is	  going	  to	  be	  published,	  
permission	    needs	  to	  be	  reobtained.	   
  • €includes	  use	  in	  an	  electronic	  form,	  provided	  it	  is	  an	  author-­‐created	  
version	  of	  the	  thesis	  on	  his/her	    own	  website	  and	  his/her	  university’s	  
repository,	  including	  UMI	  (according	  to	  the	  definition	  on	  the	    Sherpa	  
website:	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